UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934
For the quarterly period ended SeptemberJune 30, 2021
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934
For the transition period from to
Commission File Number
BRUKER CORPORATION
(Exact name of registrant as specified in its charter)
Delaware | 04-3110160 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
40 Manning Road, Billerica
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area(978) (978) 663-3660
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbols(s) | Name of each exchange on which registered | ||
Common Stock | BRKR | Nasdaq Global Select Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation(§ (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
Large accelerated filer | ☒ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Class | Outstanding at | |
Common Stock, $0.01 par value per share | 148,138,207 shares |
BRUKER CORPORATION
Quarterly Report on
For the Quarter Ended SeptemberJune 30, 2021
Index
Page | ||||||
Part I | 3 | |||||
Item 1: | 3 | |||||
3 | ||||||
4 | ||||||
5 | ||||||
7 | ||||||
Notes to Unaudited Condensed Consolidated Financial Statements | 8 | |||||
Item 2: | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 26 | ||||
Item 3: | 40 | |||||
Item 4: | 42 | |||||
Part II | 43 | |||||
Item 1: | 43 | |||||
Item 1A: | 43 | |||||
Item 2: | 43 | |||||
Item 6: | 44 | |||||
45 | ||||||
2
PART I FINANCIAL INFORMATION
ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
BRUKER CORPORATION
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions, except share and per share data)
September 30, 2021 | December 31, 2020 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 573.0 | $ | 681.8 | ||||
Short-term investments | 96.8 | 50.0 | ||||||
Accounts receivable, net | 372.1 | 335.3 | ||||||
Inventories | 732.8 | 692.3 | ||||||
Assets held for sale | 4.5 | 0 | ||||||
Other current assets | 210.1 | 165.6 | ||||||
Total current assets | 1,989.3 | 1,925.0 | ||||||
Property, plant and equipment, net | 389.4 | 395.5 | ||||||
Goodwill | 324.2 | 320.4 | ||||||
Intangible assets, net | 217.7 | 229.1 | ||||||
Assets held for sale | 0.4 | 0 | ||||||
Other long-term assets | 206.7 | 179.0 | ||||||
Total assets | $ | 3,127.7 | $ | 3,049.0 | ||||
LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS’ EQUITY | ||||||||
Current liabilities: | ||||||||
Current portion of long-term debt | $ | 109.5 | $ | 2.2 | ||||
Accounts payable | 141.1 | 134.6 | ||||||
Customer advances | 178.3 | 189.2 | ||||||
Other current liabilities | 492.3 | 465.9 | ||||||
Total current liabilities | 921.2 | 791.9 | ||||||
Long-term debt | 717.5 | 842.3 | ||||||
Other long-term liabilities | �� | 399.1 | 440.5 | |||||
Commitments and contingencies (Note 14) | 0 | 0 | ||||||
Redeemable noncontrolling interest | 0.3 | 0 | ||||||
Shareholders’ equity: | ||||||||
Preferred stock, $0.01 par value 5,000,000 shares authorized, NaN issued or outstanding | 0 | 0 | ||||||
Common stock, $0.01 par value 260,000,000 shares authorized, 174,835,498 and 174,045,610 shares issued and 151,690,664 and 151,987,081 shares outstanding at September 30, 2021 and December 31, 2020, | 1.7 | 1.7 | ||||||
Treasury stock, at cost, 23,144,834 and 22,058,529 shares at September 30, 2021 and December 31, 2020, respectively | (738.1 | ) | (667.0 | ) | ||||
Accumulated other comprehensive income (loss) | (10.7 | ) | 3.7 | |||||
Other shareholders’ equity | 1,822.7 | 1,622.8 | ||||||
Total shareholders’ equity attributable to Bruker Corporation | 1,075.6 | 961.2 | ||||||
Noncontrolling interest in consolidated subsidiaries | 14.0 | 13.1 | ||||||
Total shareholders’ equity | 1,089.6 | 974.3 | ||||||
Total liabilities, redeemable noncontrolling interest and shareholders’ equity | $ | 3,127.7 | $ | 3,049.0 | ||||
|
| June 30, |
|
| December 31, |
| ||
ASSETS |
|
|
|
|
|
| ||
Current assets: |
|
|
|
|
|
| ||
Cash and cash equivalents |
| $ | 723.0 |
|
| $ | 1,068.2 |
|
Short-term investments |
|
| 0 |
|
|
| 100.0 |
|
Accounts receivable, net |
|
| 402.6 |
|
|
| 416.9 |
|
Inventories |
|
| 759.0 |
|
|
| 710.1 |
|
Assets held for sale |
|
| 0 |
|
|
| 4.4 |
|
Other current assets |
|
| 202.9 |
|
|
| 172.2 |
|
Total current assets |
|
| 2,087.5 |
|
|
| 2,471.8 |
|
Property, plant and equipment, net |
|
| 395.0 |
|
|
| 406.1 |
|
Goodwill |
|
| 396.2 |
|
|
| 339.5 |
|
Intangible assets, net |
|
| 233.5 |
|
|
| 211.8 |
|
Other long-term assets |
|
| 272.6 |
|
|
| 220.8 |
|
Total assets |
| $ | 3,384.8 |
|
| $ | 3,650.0 |
|
LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS’ EQUITY |
|
|
|
|
|
| ||
Current liabilities: |
|
|
|
|
|
| ||
Current portion of long-term debt |
| $ | 14.0 |
|
| $ | 112.4 |
|
Accounts payable |
|
| 154.9 |
|
|
| 147.4 |
|
Customer advances |
|
| 196.7 |
|
|
| 197.5 |
|
Other current liabilities |
|
| 452.8 |
|
|
| 481.2 |
|
Total current liabilities |
|
| 818.4 |
|
|
| 938.5 |
|
Long-term debt |
|
| 1,171.0 |
|
|
| 1,221.8 |
|
Other long-term liabilities |
|
| 404.7 |
|
|
| 404.9 |
|
Commitments and contingencies (Note 14) |
|
|
|
|
|
| ||
Redeemable noncontrolling interests |
|
| 6.3 |
|
|
| 0.2 |
|
Shareholders’ equity: |
|
|
|
|
|
| ||
Preferred stock, $0.01 par value 5,000,000 shares authorized, 0ne issued or |
|
| 0 |
|
|
| 0 |
|
Common stock, $0.01 par value 260,000,000 shares authorized, 175,062,026 and |
|
| 1.7 |
|
|
| 1.7 |
|
Treasury stock, at cost, 26,738,144 and 24,151,348 shares at June 30, 2022 |
|
| (986.2 | ) |
|
| (820.3 | ) |
Accumulated other comprehensive loss, net of tax |
|
| (49.3 | ) |
|
| (8.2 | ) |
Other shareholders’ equity |
|
| 2,004.3 |
|
|
| 1,897.3 |
|
Total shareholders’ equity attributable to Bruker Corporation |
|
| 970.5 |
|
|
| 1,070.5 |
|
Noncontrolling interests in consolidated subsidiaries |
|
| 13.9 |
|
|
| 14.1 |
|
Total shareholders’ equity |
|
| 984.4 |
|
|
| 1,084.6 |
|
Total liabilities, redeemable noncontrolling interests and shareholders’ equity |
| $ | 3,384.8 |
|
| $ | 3,650.0 |
|
The accompanying notes are an integral part of these financial statements
3
BRUKER CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(in millions, except per share data)
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Product revenue | $ | 508.3 | $ | 419.6 | $ | 1,441.2 | $ | 1,111.6 | ||||||||
Service revenue | 99.0 | 90.0 | 287.8 | 244.3 | ||||||||||||
Other revenue | 1.6 | 1.8 | 5.4 | 4.1 | ||||||||||||
Total revenue | 608.9 | 511.4 | 1,734.4 | 1,360.0 | ||||||||||||
Cost of product revenue | 243.5 | 210.3 | 700.4 | 584.1 | ||||||||||||
Cost of service revenue | 56.5 | 52.6 | 165.3 | 148.4 | ||||||||||||
Cost of other revenue | 0.2 | 0.2 | 0.7 | 0.7 | ||||||||||||
Total cost of revenue | 300.2 | 263.1 | 866.4 | 733.2 | ||||||||||||
Gross profit | 308.7 | 248.3 | 868.0 | 626.8 | ||||||||||||
Operating expenses: | ||||||||||||||||
Selling, general and administrative | 141.3 | 114.6 | 407.9 | 338.2 | ||||||||||||
Research and development | 52.1 | 48.3 | 162.7 | 140.9 | ||||||||||||
Other charges, net | 2.1 | 4.2 | 9.5 | 12.2 | ||||||||||||
Total operating expenses | 195.5 | 167.1 | 580.1 | 491.3 | ||||||||||||
Operating income | 113.2 | 81.2 | 287.9 | 135.5 | ||||||||||||
Interest and other income (expense), net | (4.4 | ) | (5.9 | ) | (13.8 | ) | (15.4 | ) | ||||||||
Income before income taxes and noncontrolling interest in consolidated subsidiaries | 108.8 | 75.3 | 274.1 | 120.1 | ||||||||||||
Income tax provision | 20.7 | 20.0 | 69.5 | 30.0 | ||||||||||||
Consolidated net income | 88.1 | 55.3 | 204.6 | 90.1 | ||||||||||||
Net income attributable to noncontrolling interests in consolidated subsidiaries | 1.0 | 1.0 | 3.2 | 1.2 | ||||||||||||
Net income attributable to Bruker Corporation | $ | 87.1 | $ | 54.3 | $ | 201.4 | $ | 88.9 | ||||||||
Net income per common share attributable to Bruker Corporation shareholders: | ||||||||||||||||
Basic | $ | 0.58 | $ | 0.35 | $ | 1.33 | $ | 0.58 | ||||||||
Diluted | $ | 0.57 | $ | 0.35 | $ | 1.32 | $ | 0.57 | ||||||||
Weighted average common shares outstanding: | ||||||||||||||||
Basic | 151.4 | 153.2 | 151.5 | 153.7 | ||||||||||||
Diluted | 152.8 | 154.3 | 153.0 | 154.8 | ||||||||||||
Comprehensive income | $ | 73.1 | $ | 64.0 | $ | 188.1 | $ | 110.1 | ||||||||
Less: Comprehensive income attributable to noncontrolling interests | 0.7 | 1.4 | 0.9 | 1.5 | ||||||||||||
Less: Comprehensive loss attributable to redeemable noncontrolling interest | 0 | 0 | 0 | (0.5 | ) | |||||||||||
Comprehensive income attributable to Bruker Corporation | $ | 72.4 | $ | 62.6 | $ | 187.2 | $ | 109.1 | ||||||||
Redeemable Noncontrolling Interest | Common Shares | Common Stock Amount | Treasury Shares | Treasury Stock Amount | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Total Shareholders’ Equity Attributable to Bruker Corporation | Noncontrolling Interests in Consolidated Subsidiaries | Total Shareholders’ Equity | ||||||||||||||||||||||||||||||||||
Balance at December 31, 2020 | $ | 0 | 151,987,081 | $ | 1.7 | 22,058,529 | $ | (667.0 | ) | $ | 216.3 | $ | 1,406.5 | $ | 3.7 | $ | 961.2 | $ | 13.1 | $ | 974.3 | |||||||||||||||||||||||
Stock options exercised | 65,312 | — | 1.2 | 1.2 | 1.2 | |||||||||||||||||||||||||||||||||||||||
Restricted stock units vested | 21,821 | — | (0.1 | ) | (0.1 | ) | (0.1 | ) | ||||||||||||||||||||||||||||||||||||
Stock based compensation | 3.4 | 3.4 | 3.4 | |||||||||||||||||||||||||||||||||||||||||
Shares purchased | (530,729 | ) | 530,729 | (32.8 | ) | (32.8 | ) | (32.8 | ) | |||||||||||||||||||||||||||||||||||
Dividends declared to common stockholders ($0.04 per share) | (6.1 | ) | (6.1 | ) | (6.1 | ) | ||||||||||||||||||||||||||||||||||||||
Consolidated net income | 56.7 | 56.7 | 1.1 | 57.8 | ||||||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss) | (15.8 | ) | (15.8 | ) | (0.2 | ) | (16.0 | ) | ||||||||||||||||||||||||||||||||||||
Balance at March 31, 2021 | $ | — | 151,543,485 | $ | 1.7 | 22,589,258 | $ | (699.8 | ) | $ | 220.8 | $ | 1,457.1 | $ | (12.1 | ) | $ | 967.7 | $ | 14.0 | $ | 981.7 | ||||||||||||||||||||||
Stock options exercised | 64,783 | — | 1.0 | 1.0 | 1.0 | |||||||||||||||||||||||||||||||||||||||
Restricted stock units vested | 1,780 | — | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||
Stock based compensation | 3.6 | 3.6 | 3.6 | |||||||||||||||||||||||||||||||||||||||||
Shares purchased | (555,576 | ) | 555,576 | (38.3 | ) | (38.3 | ) | (38.3 | ) | |||||||||||||||||||||||||||||||||||
Dividends declared to common stockholders ($0.04 per share) | (6.0 | ) | (6.0 | ) | (6.0 | ) | ||||||||||||||||||||||||||||||||||||||
Formation of Acuity Spatial Genomics Inc. | 0.3 | — | — | |||||||||||||||||||||||||||||||||||||||||
Consolidated net income | — | 57.6 | 57.6 | 1.1 | 58.7 | |||||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss) | 16.4 | 16.4 | (1.7 | ) | 14.7 | |||||||||||||||||||||||||||||||||||||||
Balance at June 30, 2021 | $ | 0.3 | 151,054,472 | $ | 1.7 | 23,144,834 | $ | (738.1 | ) | $ | 225.4 | $ | 1,508.7 | $ | 4.3 | $ | 1,002.0 | $ | 13.4 | $ | 1,015.4 | |||||||||||||||||||||||
Stock options exercised | 385,597 | — | 8.3 | 8.3 | 8.3 | |||||||||||||||||||||||||||||||||||||||
Restricted stock units vested | 250,595 | — | (4.5 | ) | (4.5 | ) | (4.5 | ) | ||||||||||||||||||||||||||||||||||||
Stock based compensation | 3.8 | 3.8 | 3.8 | |||||||||||||||||||||||||||||||||||||||||
Dividends declared to common stockholders ($0.04 per share) | (6.1 | ) | (6.1 | ) | (6.1 | ) | ||||||||||||||||||||||||||||||||||||||
Consolidated net income | — | 87.1 | 87.1 | 1.0 | 88.1 | |||||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss) | (15.0 | ) | (15.0 | ) | (0.4 | ) | (15.4 | ) | ||||||||||||||||||||||||||||||||||||
Balance at September 30, 2021 | $ | 0.3 | 151,690,664 | $ | 1.7 | 23,144,834 | $ | (738.1 | ) | $ | 233.0 | $ | 1,589.7 | $ | (10.7 | ) | $ | 1,075.6 | $ | 14.0 | $ | 1,089.6 | ||||||||||||||||||||||
|
| Three Months Ended |
|
| Six Months Ended |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
Product revenue |
| $ | 485.8 |
|
| $ | 474.3 |
|
| $ | 976.2 |
|
| $ | 932.9 |
|
Service revenue |
|
| 100.9 |
|
|
| 94.7 |
|
|
| 204.1 |
|
|
| 188.8 |
|
Other revenue |
|
| 1.7 |
|
|
| 1.8 |
|
|
| 3.1 |
|
|
| 3.8 |
|
Total revenue |
|
| 588.4 |
|
|
| 570.8 |
|
|
| 1,183.4 |
|
|
| 1,125.5 |
|
Cost of product revenue |
|
| 230.1 |
|
|
| 236.0 |
|
|
| 459.1 |
|
|
| 456.9 |
|
Cost of service revenue |
|
| 60.1 |
|
|
| 54.1 |
|
|
| 119.7 |
|
|
| 108.8 |
|
Cost of other revenue |
|
| 0 |
|
|
| 0.1 |
|
|
| 0.1 |
|
|
| 0.5 |
|
Total cost of revenue |
|
| 290.2 |
|
|
| 290.2 |
|
|
| 578.9 |
|
|
| 566.2 |
|
Gross profit |
|
| 298.2 |
|
|
| 280.6 |
|
|
| 604.5 |
|
|
| 559.3 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Selling, general and administrative |
|
| 152.2 |
|
|
| 134.8 |
|
|
| 297.9 |
|
|
| 266.6 |
|
Research and development |
|
| 59.6 |
|
|
| 55.8 |
|
|
| 116.2 |
|
|
| 110.6 |
|
Other charges, net |
|
| 12.5 |
|
|
| 4.4 |
|
|
| 20.0 |
|
|
| 7.4 |
|
Total operating expenses |
|
| 224.3 |
|
|
| 195.0 |
|
|
| 434.1 |
|
|
| 384.6 |
|
Operating income |
|
| 73.9 |
|
|
| 85.6 |
|
|
| 170.4 |
|
|
| 174.7 |
|
Interest and other income (expense), net |
|
| (4.3 | ) |
|
| (5.6 | ) |
|
| (6.8 | ) |
|
| (9.4 | ) |
Income before income taxes and noncontrolling interests in |
|
| 69.6 |
|
|
| 80.0 |
|
|
| 163.6 |
|
|
| 165.3 |
|
Income tax provision |
|
| 19.9 |
|
|
| 21.3 |
|
|
| 51.8 |
|
|
| 48.8 |
|
Consolidated net income |
|
| 49.7 |
|
|
| 58.7 |
|
|
| 111.8 |
|
|
| 116.5 |
|
Net income attributable to noncontrolling interests in consolidated subsidiaries |
|
| 0.2 |
|
|
| 1.1 |
|
|
| 0.7 |
|
|
| 2.2 |
|
Net income attributable to Bruker Corporation |
| $ | 49.5 |
|
| $ | 57.6 |
|
| $ | 111.1 |
|
| $ | 114.3 |
|
Net income per common share attributable to Bruker Corporation |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Basic |
| $ | 0.33 |
|
| $ | 0.38 |
|
| $ | 0.74 |
|
| $ | 0.75 |
|
Diluted |
| $ | 0.33 |
|
| $ | 0.38 |
|
| $ | 0.74 |
|
| $ | 0.75 |
|
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Basic |
|
| 149.0 |
|
|
| 151.3 |
|
|
| 149.7 |
|
|
| 151.6 |
|
Diluted |
|
| 149.8 |
|
|
| 152.9 |
|
|
| 150.6 |
|
|
| 153.0 |
|
Comprehensive income |
| $ | 15.9 |
|
| $ | 73.4 |
|
| $ | 69.1 |
|
| $ | 115.0 |
|
Less: Comprehensive income (loss) attributable to noncontrolling |
|
| (0.4 | ) |
|
| (0.7 | ) |
|
| (0.2 | ) |
|
| 0.2 |
|
Less: Comprehensive loss attributable to redeemable |
|
| (0.5 | ) |
|
| 0 |
|
|
| (0.7 | ) |
|
| 0 |
|
Comprehensive income attributable to Bruker Corporation |
| $ | 16.8 |
|
| $ | 74.1 |
|
| $ | 70.0 |
|
| $ | 114.8 |
|
The accompanying notes are an integral part of these financial statements
4
BRUKER CORPORATION
(in millions, except per share data)
Redeemable Noncontrolling Interest | Common Shares | Common Stock Amount | Treasury Shares | Treasury Stock Amount | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Total Shareholders’ Equity Attributable to Bruker Corporation | Noncontrolling Interests in Consolidated Subsidiaries | Total Shareholders’ Equity | ||||||||||||||||||||||||||||||||||
Balance at December 31, 2019 | $ | 21.1 | 154,155,798 | $ | 1.7 | 19,346,577 | $ | (543.8 | ) | $ | 199.7 | $ | 1,274.7 | $ | (25.5 | ) | $ | 906.8 | $ | 10.3 | $ | 917.1 | ||||||||||||||||||||||
Stock options exercised | 30,182 | — | 0.7 | 0.7 | 0.7 | |||||||||||||||||||||||||||||||||||||||
Restricted stock units vested | 40,516 | — | (0.1 | ) | (0.1 | ) | (0.1 | ) | ||||||||||||||||||||||||||||||||||||
Stock based compensation | 3.0 | 3.0 | 3.0 | |||||||||||||||||||||||||||||||||||||||||
Cash dividends paid to common stockholders ($0.04 per share) | — | (6.2 | ) | (6.2 | ) | (1.2 | ) | (7.4 | ) | |||||||||||||||||||||||||||||||||||
Acquired remaining 20% interest in Hain LifeScience GmbH | (20.6 | ) | (1.3 | ) | (1.3 | ) | (1.3 | ) | ||||||||||||||||||||||||||||||||||||
Consolidated net income | — | 10.5 | 10.5 | 0.1 | 10.6 | |||||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss) | (0.5 | ) | 2.2 | 2.2 | (0.2 | ) | 2.0 | |||||||||||||||||||||||||||||||||||||
Balance at March 31, 2020 | $ | — | 154,226,496 | $ | 1.7 | 19,346,577 | $ | (543.8 | ) | $ | 203.3 | $ | 1,277.7 | $ | (23.3 | ) | $ | 915.6 | $ | 9.0 | $ | 924.6 | ||||||||||||||||||||||
Stock options exercised | 61,968 | — | 1.3 | 1.3 | 1.3 | |||||||||||||||||||||||||||||||||||||||
Restricted stock units vested | 3,510 | — | (0.1 | ) | (0.1 | ) | (0.1 | ) | ||||||||||||||||||||||||||||||||||||
Stock based compensation | 2.8 | 2.8 | 2.8 | |||||||||||||||||||||||||||||||||||||||||
Shares Repurchased | (1,214,282 | ) | 1,214,282 | (50.0 | ) | (50.0 | ) | (50.0 | ) | |||||||||||||||||||||||||||||||||||
Cash dividends paid to common stockholders ($0.04 per share) | (6.1 | ) | (6.1 | ) | (6.1 | ) | ||||||||||||||||||||||||||||||||||||||
Consolidated net income | 24.1 | 24.1 | 0.1 | 24.2 | ||||||||||||||||||||||||||||||||||||||||
Other comprehensive income | 9.8 | 9.8 | 0.1 | 9.9 | ||||||||||||||||||||||||||||||||||||||||
Balance at June 30, 2020 | $ | — | 153,077,692 | $ | 1.7 | 20,560,859 | $ | (593.8 | ) | $ | 207.3 | $ | 1,295.7 | $ | (13.5 | ) | $ | 897.4 | $ | 9.2 | $ | 906.6 | ||||||||||||||||||||||
Stock options exercised | 25,461 | — | 0.5 | 0.5 | 0.5 | |||||||||||||||||||||||||||||||||||||||
Restricted stock units vested | 208,652 | — | (1.2 | ) | (1.2 | ) | (1.2 | ) | ||||||||||||||||||||||||||||||||||||
Stock based compensation | 4.1 | 4.1 | 4.1 | |||||||||||||||||||||||||||||||||||||||||
Shares Repurchased | (127,278 | ) | 127,278 | (5.0 | ) | (5.0 | ) | (5.0 | ) | |||||||||||||||||||||||||||||||||||
Cash dividends paid to common stockholders ($0.04 per share) | (6.3 | ) | (6.3 | ) | (6.3 | ) | ||||||||||||||||||||||||||||||||||||||
Consolidated net income | 54.3 | 54.3 | 1.0 | 55.3 | ||||||||||||||||||||||||||||||||||||||||
Other comprehensive income | 8.3 | 8.3 | 0.4 | 8.7 | ||||||||||||||||||||||||||||||||||||||||
Balance at September 30, 2020 | $ | — | 153,184,527 | $ | 1.7 | 20,688,137 | $ | (598.8 | ) | $ | 210.7 | $ | 1,343.7 | $ | (5.2 | ) | $ | 952.1 | $ | 10.6 | $ | 962.7 | ||||||||||||||||||||||
|
| Redeemable |
|
|
| Common |
|
| Common |
|
| Treasury |
|
| Treasury |
|
| Additional |
|
| Retained |
|
| Accumulated |
|
| Total |
|
| Noncontrolling |
|
| Total |
| |||||||||||
Balance at December 31, 2021 |
| $ | 0.2 |
|
|
|
| 150,753,687 |
|
| $ | 1.7 |
|
|
| 24,151,348 |
|
| $ | (820.3 | ) |
| $ | 237.8 |
|
| $ | 1,659.5 |
|
| $ | (8.2 | ) |
| $ | 1,070.5 |
|
| $ | 14.1 |
|
| $ | 1,084.6 |
|
Stock options exercised |
|
| — |
|
|
|
| 118,630 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 3.1 |
|
|
| — |
|
|
| — |
|
|
| 3.1 |
|
|
| — |
|
|
| 3.1 |
|
Restricted stock units vested |
|
| — |
|
|
|
| 22,440 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Stock-based compensation |
|
| — |
|
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 3.8 |
|
|
| — |
|
|
| — |
|
|
| 3.8 |
|
|
| — |
|
|
| 3.8 |
|
Shares repurchased |
|
| — |
|
|
|
| (1,603,055 | ) |
|
| — |
|
|
| 1,603,055 |
|
|
| (105.6 | ) |
|
| — |
|
|
| — |
|
|
| — |
|
|
| (105.6 | ) |
|
| — |
|
|
| (105.6 | ) |
Cash dividends paid to common shareholders |
|
| — |
|
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (7.5 | ) |
|
| — |
|
|
| (7.5 | ) |
|
| — |
|
|
| (7.5 | ) |
Consolidated net income |
|
| — |
|
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 61.6 |
|
|
| — |
|
|
| 61.6 |
|
|
| 0.5 |
|
|
| 62.1 |
|
PreOmics Acquisition - other shareholders |
|
| 6.8 |
|
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Other comprehensive loss |
|
| (0.2 | ) |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (8.9 | ) |
|
| (8.9 | ) |
|
| (0.3 | ) |
|
| (9.2 | ) |
Balance at March 31, 2022 |
| $ | 6.8 |
|
|
|
| 149,291,702 |
|
| $ | 1.7 |
|
|
| 25,754,403 |
|
| $ | (925.9 | ) |
| $ | 244.7 |
|
| $ | 1,713.6 |
|
| $ | (17.1 | ) |
| $ | 1,017.0 |
|
| $ | 14.3 |
|
| $ | 1,031.3 |
|
Stock options exercised |
|
| — |
|
|
|
| 14,110 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 0.2 |
|
|
| — |
|
|
| — |
|
|
| 0.2 |
|
|
| — |
|
|
| 0.2 |
|
Restricted stock units vested |
|
| — |
|
|
|
| 1,811 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Stock-based compensation |
|
| — |
|
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 3.8 |
|
|
| — |
|
|
| — |
|
|
| 3.8 |
|
|
| — |
|
|
| 3.8 |
|
Shares repurchased |
|
| — |
|
|
|
| (983,741 | ) |
|
| — |
|
|
| 983,741 |
|
|
| (60.3 | ) |
|
| — |
|
|
| — |
|
|
| — |
|
|
| (60.3 | ) |
|
| — |
|
|
| (60.3 | ) |
Cash dividends paid to common shareholders |
|
| — |
|
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (7.5 | ) |
|
| — |
|
|
| (7.5 | ) |
|
| — |
|
|
| (7.5 | ) |
Consolidated net income |
|
| (0.2 | ) |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 49.5 |
|
|
| — |
|
|
| 49.5 |
|
|
| 0.4 |
|
|
| 49.9 |
|
Other comprehensive loss |
|
| (0.3 | ) |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (32.2 | ) |
|
| (32.2 | ) |
|
| (0.8 | ) |
|
| (33.0 | ) |
Balance at June 30, 2022 |
| $ | 6.3 |
|
|
|
| 148,323,882 |
|
| $ | 1.7 |
|
|
| 26,738,144 |
|
| $ | (986.2 | ) |
| $ | 248.7 |
|
| $ | 1,755.6 |
|
| $ | (49.3 | ) |
| $ | 970.5 |
|
| $ | 13.9 |
|
| $ | 984.4 |
|
The accompanying notes are an integral part of these financial statements
5
BRUKER CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)
Nine Months Ended September 30, | ||||||||
2021 | 2020 | |||||||
Cash flows from operating activities: | ||||||||
Consolidated net income | $ | 204.6 | $ | 90.1 | ||||
Adjustments to reconcile consolidated net income to cash flows from operating activities: | ||||||||
Depreciation and amortization | 66.1 | 58.7 | ||||||
Stock-based compensation expense | 11.9 | 10.9 | ||||||
Deferred income taxes | (6.5 | ) | 0.5 | |||||
Other non-cash expenses, net | 24.8 | 25.5 | ||||||
Changes in operating assets and liabilities, net of acquisitions and divestitures: | ||||||||
Accounts receivable | (47.7 | ) | 36.9 | |||||
Inventories | (81.3 | ) | (109.7 | ) | ||||
Accounts payable and accrued expenses | 45.9 | (15.3 | ) | |||||
Income taxes payable, net | (33.4 | ) | (9.1 | ) | ||||
Deferred revenue | 19.4 | 20.1 | ||||||
Customer advances | (9.5 | ) | 32.4 | |||||
Other changes in operating assets and liabilities, net | (50.5 | ) | (11.8 | ) | ||||
Net cash provided by operating activities | 143.8 | 129.2 | ||||||
Cash flows from investing activities: | ||||||||
Purchases of short-term investments | (48.0 | ) | (100.0 | ) | ||||
Maturity of short-term investments | 0.7 | 56.1 | ||||||
Purchases of investments held to maturity | (0.5 | ) | 0 | |||||
Cash paid for acquisitions, net of cash acquired | (45.0 | ) | (58.8 | ) | ||||
Purchases of property, plant and equipment | (63.6 | ) | (68.4 | ) | ||||
Proceeds from sales of property, plant and equipment | 4.0 | 0.1 | ||||||
Net proceeds from cross currency swap agreements | 8.6 | 7.1 | ||||||
Net cash used in investing activities | (143.8 | ) | (163.9 | ) | ||||
Cash flows from financing activities: | ||||||||
Repayments of revolving lines of credit | 0 | (305.1 | ) | |||||
Proceeds from revolving lines of credit | — | 297.5 | ||||||
Repayment of other debt | (2.2 | ) | (0.4 | ) | ||||
Proceeds from other debt | 0.4 | 0 | ||||||
Payment of deferred financing costs | — | (0.1 | ) | |||||
Proceeds from issuance of common stock, net | 5.9 | 1.1 | ||||||
Payment of contingent consideration | (0.4 | ) | (6.2 | ) | ||||
Payment of dividends to common stockholders | (18.2 | ) | (18.5 | ) | ||||
Purchases of common stock | (71.1 | ) | (54.4 | ) | ||||
Cash payments to noncontrolling interest | 0 | (1.2 | ) | |||||
Net cash used in financing activities | (85.6 | ) | (87.3 | ) | ||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash | (23.4 | ) | 10.7 | |||||
Net change in cash, cash equivalents and restricted cash | (109.0 | ) | (111.3 | ) | ||||
Cash, cash equivalents and restricted cash at beginning of period | 685.5 | 681.9 | ||||||
Cash, cash equivalents and restricted cash at end of period | $ | 576.5 | $ | 570.6 | ||||
Supplemental disclosure of cash flow information: | ||||||||
Restricted cash period beginning balance | $ | 3.7 | $ | 3.6 | ||||
Restricted cash period ending balance | $ | 3.5 | $ | 3.5 | ||||
|
| Redeemable |
|
|
| Common |
|
| Common |
|
| Treasury |
|
| Treasury |
|
| Additional |
|
| Retained |
|
| Accumulated |
|
| Total |
|
| Noncontrolling |
|
| Total |
| |||||||||||
Balance at December 31, 2020 |
| $ | — |
|
|
|
| 151,987,081 |
|
| $ | 1.7 |
|
|
| 22,058,529 |
|
| $ | (667.0 | ) |
| $ | 216.3 |
|
| $ | 1,406.5 |
|
| $ | 3.7 |
|
| $ | 961.2 |
|
| $ | 13.1 |
|
| $ | 974.3 |
|
Stock options exercised |
|
| — |
|
|
|
| 65,312 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 1.2 |
|
|
| — |
|
|
| — |
|
|
| 1.2 |
|
|
| — |
|
|
| 1.2 |
|
Restricted stock units vested |
|
| — |
|
|
|
| 21,821 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (0.1 | ) |
|
| — |
|
|
| — |
|
|
| (0.1 | ) |
|
| — |
|
|
| (0.1 | ) |
Stock-based compensation |
|
| — |
|
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 3.4 |
|
|
| — |
|
|
| — |
|
|
| 3.4 |
|
|
| — |
|
|
| 3.4 |
|
Shares repurchased |
|
| — |
|
|
|
| (530,729 | ) |
|
| — |
|
|
| 530,729 |
|
|
| (32.8 | ) |
|
| — |
|
|
| — |
|
|
| — |
|
|
| (32.8 | ) |
|
| — |
|
|
| (32.8 | ) |
Cash dividends paid to common shareholders |
|
| — |
|
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (6.1 | ) |
|
| — |
|
|
| (6.1 | ) |
|
| — |
|
|
| (6.1 | ) |
Consolidated net income |
|
| — |
|
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 56.7 |
|
|
| — |
|
|
| 56.7 |
|
|
| 1.1 |
|
|
| 57.8 |
|
Other comprehensive loss |
|
| — |
|
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (15.8 | ) |
|
| (15.8 | ) |
|
| (0.2 | ) |
|
| (16.0 | ) |
Balance at March 31, 2021 |
| $ | — |
|
|
|
| 151,543,485 |
|
| $ | 1.7 |
|
|
| 22,589,258 |
|
| $ | (699.8 | ) |
| $ | 220.8 |
|
| $ | 1,457.1 |
|
| $ | (12.1 | ) |
| $ | 967.7 |
|
| $ | 14.0 |
|
| $ | 981.7 |
|
Stock options exercised |
|
| — |
|
|
|
| 64,783 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 1.0 |
|
|
| — |
|
|
| — |
|
|
| 1.0 |
|
|
| — |
|
|
| 1.0 |
|
Restricted stock units vested |
|
| — |
|
|
|
| 1,780 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Stock-based compensation |
|
| — |
|
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 3.6 |
|
|
| — |
|
|
| — |
|
|
| 3.6 |
|
|
| — |
|
|
| 3.6 |
|
Shares repurchased |
|
| — |
|
|
|
| (555,576 | ) |
|
| — |
|
|
| 555,576 |
|
|
| (38.3 | ) |
|
| — |
|
|
| — |
|
|
| — |
|
|
| (38.3 | ) |
|
| — |
|
|
| (38.3 | ) |
Cash dividends paid to common shareholders |
|
| — |
|
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (6.0 | ) |
|
| — |
|
|
| (6.0 | ) |
|
| — |
|
|
| (6.0 | ) |
Formation of Acuity Spatial Genomics Inc. |
|
| 0.3 |
|
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Consolidated net income |
|
| — |
|
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 57.6 |
|
|
| — |
|
|
| 57.6 |
|
|
| 1.1 |
|
|
| 58.7 |
|
Other comprehensive income (loss) |
|
| — |
|
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 16.4 |
|
|
| 16.4 |
|
|
| (1.7 | ) |
|
| 14.7 |
|
Balance at June 30, 2021 |
| $ | 0.3 |
|
|
|
| 151,054,472 |
|
| $ | 1.7 |
|
|
| 23,144,834 |
|
| $ | (738.1 | ) |
| $ | 225.4 |
|
| $ | 1,508.7 |
|
| $ | 4.3 |
|
| $ | 1,002.0 |
|
| $ | 13.4 |
|
| $ | 1,015.4 |
|
The accompanying notes are an integral part of these financial statements
6
7
BRUKER CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2022
Bruker Corporation, together with its consolidated subsidiaries (Bruker or the Company), develops, manufactures and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. Many of the Company’s products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. The Company’s products address the rapidly evolving needsneeds of a diverse array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in vitro diagnostics, nanotechnology and materials science research.
The Company has 4 operating segments,Group3reportable3 reportable segments,segment, BSI NANO segmentBEST.
For financial reporting purposes, the Bruker BioSpinGroup and Bruker CALID Group operating segments are aggregated into the reportable BSI Life Science segment because each has similar economic characteristics, production processes, service offerings, types and classes of customers, methods of distribution and regulatory environments.
Bruker BioSpin
Bruker CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection)
The BSI NANONano segment designs, manufactures and distributes advanced X-ray instruments; atomic force microscopy instrumentation; advanced fluorescence optical microscopy instruments; analytical tools for electron microscopes and X-ray metrology; defect-detection equipment for semiconductor process control; handheld, portable and mobile X-ray fluorescence spectrometry instruments; spark optical emission spectroscopy systems; chip cytometry products and services for targeted spatial proteomics, multi-omic services,services; and products and services for spatial genomics research. Customers of the BSI NANONano segment include academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses involved in materials research and life science research analysis.
The BEST reportable segment develops and manufactures superconducting andhealthcare, renewable energy, energy infrastructure, healthcare and “big science” research. The segment focuses on metallic low temperature superconductors for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications.
The unaudited condensed consolidated financial statements represent the consolidated accounts of the Company. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of SeptemberJune 30, 20212022 and December 31, 2020,2021, and for the three and ninesix months ended SeptemberJune 30, 20212022 and 2020,2021, have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, the financial information presented herein does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair statement have been included. The results for interim periods are not necessarily indicative of the results expected for any other interim period or the full year.
At SeptemberJune 30, 2021,2022, the Company’s significant accounting policies, which are detailed in the Company’s Annual Report on Form2020,2021, have not changed.
8
Risks &and Uncertainties
The Company is subject to risks common to its industry including, but not limited to, global economic conditions, (including increasing inflation), rapid technological change, government and academic funding levels, the impact of the
The impact of the
Impacts to the Company’s business since the beginning of the pandemic have included temporary closures in 2020 of many of the Company’s government and university customers and suppliers, disruptions or restrictions on employees’ and customers’ ability to travel, and delays in product installations or shipments to and from affected countries. In an effort to halt the outbreak ofsomemany of these restrictions are looseninghave loosened in certain jurisdictions, including the United States and Europe, some markets have returned and others may return to restrictions in the face of increases in newnew strainsmore contagious variants or subvariants of the virus. A numbervirus emerge or spread. Many of states, including California, Massachusetts and New Jersey where the CompanyCompany's employees in jurisdictions in which it has significant operations have implementedre-openingpolicies as vaccines to protect against the virus continue to be administered. However, many of the Company’s employees in these areas continue to work remotely, and manyre-openingshave been delayed or pulled back as the virus continues to spread and as new strains of the virus emerge.remotely. In addition, while some parts of the world are beginning to resumepre-pandemicbusiness operations, certain Asia Pacific geographies where the Company operates are continuing to experience significantdisruptions. disruptions, including extensive and sustained lockdowns. Much of the commercial activity in sales and marketing, and customer demonstrations and applications training, is still either being conducted remotely or postponed. Even where customers havestrainsvariants or subvariants of the virus, particularly any new strainsvariants or subvariants which are more easily transmitted or which are resistant to existing vaccines, may require the Company or its customers to close or partially close operations once again. These travel restrictions, business closures and operating reductions at Bruker, customers, distributors, and/or suppliers have in the past adversely impacted and may continue to adversely impact the Company’s operations worldwide, including the ability to manufacture, sell or distribute products, as well as cause temporary closures of foreign distributors, or the facilities of suppliers or customers. Global supply chains, including for semiconductor chips, components and raw materials such as copper, have been disrupted, causing shortages, which could impacthas impacted the Company’s ability to manufacture or supply its products. The Company could also experience increased compensation expenses associated with employee recruiting and employee retention to the extent employment opportunities continue to multiply post-pandemic, causing the search for and retention of talent to become more competitive. This disruption of the Company’s employees, distributors, suppliers and customers has historically impacted and may continueis continuing to impact the Company’s global sales and operating results.
Further, on September 9, 2021, President Biden directedwhile the Department of Labor’s Occupational Safety and Health Administration (“OSHA”) to issue an Emergency Temporary Standard (“ETS”) requiring that all employers with at least 100 employees ensure that their employees are fully vaccinated forCOVID-19by January 4, 2022 or obtain a negativeCOVID-19test at least once a week. The OSHA ETS was issued on November 4, 2021. President Biden also issued an Executive Order requiring certainCOVID-19precautions for government contractors and their subcontractors, including mandatory employee vaccination (subject to medical and religious exemptions). ItCompany is not currently possiblesubject to predict with any certainty the exact impact on the Company of the OSHA ETS or the requirements for government contractors and their subcontractors. Anyvaccine mandate, any requirement to mandatethe Company’sits workforce or require the Company’s unvaccinated employees to be tested weekly could result in employee attrition and difficulty securing future labor needs and may have an adverse effect on future profit margins. In addition,operations. The Company's policy continues to encourage its employees to be fully vaccinated against COVID-19.
The Company is continuing to monitor and assess the effects of the COVID-19 pandemic on commercial operations in 2022. However, the Company cannot at this time accurately predict what effects these conditions will ultimately have on future operations due to uncertainties relating to the duration of the outbreak, including the impact of any requirementresurgence of the virus or the continued emergence or spread of certain variants or subvariants, the effectiveness and availability of vaccines, (including to impose obligations onprotect against any new variants or subvariants), the Company’s suppliers under the Executive Order covering government contractorswillingness of individuals to receive vaccines and their subcontractors could impact the price and continuity of supply of raw materialsboosters, and the Company’s resultslength or severity of operationstravel restrictions, business closures and other safety and precautionary measures imposed by the governments of impacted countries. The pandemic has also adversely affected the economies and financial condition could be adversely affected.
9
The Company has experiencedmay experience supply chain interruptions as a result of the COVID-19 pandemic.pandemic, general global economic conditions, including inflation and the threat of a potential recession, a tighter labor market and other factors including natural events and disasters. Various factors, including increased demand for certain components and production delays, and other natural events and disasters, are contributing to shortages of certain components used in the Company’s products and increased difficulties in the Company’s ability to obtain a consistent supply of materials at stable pricing levels. Supply shortages and longer lead times for components used in the Company’s products, including limited source components, canhas resulted and may continue to result in significant additional costs and inefficiencies in manufacturing. A shortage of key components has caused and may continue to cause a significant disruptiondisruptions to the Company’s production activities, which couldhas had and may continue to have a substantialan adverse effect on the Company’s financial condition or results of operations. If the Company is unsuccessful in resolving any such component shortages in a timely manner, the Company could experience a significant adverseThese factors have impacted and may continue to impact on the timing of itsthe Company's revenue, and have also resulted, and may result in a possible lossdelay of revenue, orand an increase in manufacturing costs, anyall of which would have a material adverseadversely impacted and may continue to adversely impact on the Company’s operating results.
The preparation of the unaudited condensed consolidated financial statements requires the Company to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis the Company evaluates estimates, judgments and methodologies. Changes in estimates are recorded in the period in which they become known. The Company bases estimates on historical experience and on various other assumptions that they believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which theinformation that may emergedevelopments concerningCOVID-19,new strains of the virus, the effectivenessCOVID-19 pandemic, global supply chain and availability ofCOVID-19vaccines or individuals’ willingness to receive vaccines, and the actions taken to contain or treat the virus, as well as the economic impact on local, regional, national and international customers and markets.various global conflicts. The Company has made estimates of the impact of
In March 2020, the FASBFinancial Accounting Standards Board ("FASB") issued Accounting Standards Updates (“ASU”Update ("ASU")(“ (“ASU
10
The following tabletables presents the Company’s revenues by Group and End Customer Geography (dollars in(in millions):
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Revenue by Group: | ||||||||||||||||
Bruker BioSpin | $ | 186.5 | $ | 152.1 | $ | 494.4 | $ | 398.1 | ||||||||
Bruker CALID | 194.2 | 171.3 | 579.9 | 444.5 | ||||||||||||
Bruker Nano | 174.9 | 147.1 | 504.6 | 392.7 | ||||||||||||
BEST | 57.0 | 43.8 | 166.0 | 134.8 | ||||||||||||
Eliminations | (3.7 | ) | (2.9 | ) | (10.5 | )�� | (10.1 | ) | ||||||||
Total revenue | $ | 608.9 | $ | 511.4 | $ | 1,734.4 | $ | 1,360.0 | ||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Revenue by End Customer Geography: | ||||||||||||||||
United States | $ | 163.2 | $ | 120.1 | $ | 442.0 | $ | 332.1 | ||||||||
Germany | 55.5 | 50.4 | 186.4 | 134.9 | ||||||||||||
Rest of Europe | 155.4 | 142.9 | 459.9 | 357.7 | ||||||||||||
Asia Pacific | 191.6 | 160.0 | 525.8 | 433.3 | ||||||||||||
Other | 43.2 | 38.0 | 120.3 | 102.0 | ||||||||||||
Total revenue | $ | 608.9 | $ | 511.4 | $ | 1,734.4 | $ | 1,360.0 | ||||||||
|
| Three Months Ended |
|
| Six Months Ended |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
Revenue by Group: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Bruker BioSpin |
| $ | 159.8 |
|
| $ | 148.5 |
|
| $ | 317.6 |
|
| $ | 307.9 |
|
Bruker CALID |
|
| 190.3 |
|
|
| 193.3 |
|
|
| 393.5 |
|
|
| 385.7 |
|
Bruker Nano |
|
| 182.2 |
|
|
| 175.3 |
|
|
| 360.7 |
|
|
| 329.7 |
|
BEST |
|
| 59.2 |
|
|
| 56.6 |
|
|
| 118.9 |
|
|
| 109.0 |
|
Eliminations |
|
| (3.1 | ) |
|
| (2.9 | ) |
|
| (7.3 | ) |
|
| (6.8 | ) |
Total revenue |
| $ | 588.4 |
|
| $ | 570.8 |
|
| $ | 1,183.4 |
|
| $ | 1,125.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
| Three Months Ended |
|
| Six Months Ended |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
Revenue by End Customer Geography: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
United States |
| $ | 171.5 |
|
| $ | 159.8 |
|
| $ | 326.5 |
|
| $ | 278.8 |
|
Germany |
|
| 67.3 |
|
|
| 60.8 |
|
|
| 125.8 |
|
|
| 130.9 |
|
Rest of Europe |
|
| 130.3 |
|
|
| 154.7 |
|
|
| 273.7 |
|
|
| 304.5 |
|
China |
|
| 93.1 |
|
|
| 80.4 |
|
|
| 179.4 |
|
|
| 147.2 |
|
Rest of Asia Pacific |
|
| 83.4 |
|
|
| 73.3 |
|
|
| 186.0 |
|
|
| 187.0 |
|
Other |
|
| 42.8 |
|
|
| 41.8 |
|
|
| 92.0 |
|
|
| 77.1 |
|
Total revenue |
| $ | 588.4 |
|
| $ | 570.8 |
|
| $ | 1,183.4 |
|
| $ | 1,125.5 |
|
Revenue for the Company recognized at a point in time versus over time is as follows (dollars in(in millions):
|
| Three Months Ended |
|
| Six Months Ended |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
Revenue recognized at a point in time |
| $ | 509.2 |
|
| $ | 492.2 |
|
| $ | 1,023.2 |
|
| $ | 972.2 |
|
Revenue recognized over time |
|
| 79.2 |
|
|
| 78.6 |
|
|
| 160.2 |
|
|
| 153.3 |
|
Total revenue |
| $ | 588.4 |
|
| $ | 570.8 |
|
| $ | 1,183.4 |
|
| $ | 1,125.5 |
|
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Revenue recognized at a point in time | $ | 530.8 | $ | 442.2 | $ | 1,503.0 | $ | 1,174.0 | ||||||||
Revenue recognized over time | 78.1 | 69.2 | 231.4 | 186.0 | ||||||||||||
Total revenue | $ | 608.9 | $ | 511.4 | $ | 1,734.4 | $ | 1,360.0 | ||||||||
Remaining Performance Obligations
Remaining performance obligations represent the aggregate transaction price allocated to a promise to transfer a good or service that is fully or partially unsatisfied at the end of the period. As of SeptemberJune 30, 2021,2022, remaining performance obligations were approximately $2,035.9$2,082.3million. The Company expects to recognize revenue on approximately 68.4%76% of the remaining performance obligations over the next twelve months and the remaining performance obligations primarily within one to three years.
Contract Balances
The timing of revenue recognition, billings and cash collections results in billed accounts receivable, note receivables and unbilled receivables (contract assets) and deferred revenue, customer deposits and billings in excess of revenue recognized (contract liabilities) on the Company’s unaudited condensed consolidated balance sheets.
Contract assets—
11
Contract liabilities—
The impact of all acquisitions and investments in other entities during the nine months ended September 30, 2021, individually and collectively, on revenues, net income and total assets wasCompany has not material and accordingly,presented pro forma financial information reflecting all acquisitions has not been presented.
2022
PreOmics GmbH
On August 24, 2021,
Concurrent with the potentialacquisition, the Company entered into an agreement with the noncontrolling interest holders that provides the Company with the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining 25.85% of PreOmics for additional considerationcash at a contractually defined redemption value for both the original founders and other shareholders of upPreOmics, exercisable beginning in 2026. The fair value of these rights has been bifurcated into two financial instruments to $4.0 millionseparately account for the amounts attributable to the founders and the amount attributable to other shareholders.
The rights (embedded derivative) associated with the founders can be accelerated, at a discounted redemption value, upon certain events related to post combination employment services. As the options are tied to continued employment, the Company classified the hybrid instrument (noncontrolling interest with an embedded derivative) as a long-term liability on the condensed consolidated balance sheet. The hybrid instrument associated with the founders is initially measured at fair value and subsequent to the acquisition, the carrying value of the hybrid instrument is remeasured to fair value with changes recorded to stock-based compensation expense in proportion to the requisite service period vested.
The rights associated with the other noncontrolling interest shareholders are contingently redeemable at the option of the other noncontrolling interest shareholders. As redemption of the rights is contingently redeemable at the option of the noncontrolling interest shareholders, the Company classifies the carrying amount of the redeemable noncontrolling interest in the mezzanine section on the consolidated balance sheet, which is presented above the equity section and below liabilities. The redeemable noncontrolling interest is initially measured at fair value and subsequently at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on revenuethe contractually defined redemption value and gross margin achievements inits carrying amount adjusted for net income (loss) attributable to the calendarnoncontrolling interest. Adjustments to the carrying value of the redeemable noncontrolling interest are recorded through retained earnings.
The Company expects to complete the fair value allocation during the measurement period. The amortization period for the intangible assets acquired is nine years 2022 for technology, and 2023. SCI is a manufacturer of advanced metrology systemstwelve years for the trade name and analysis software and serves major companies in the semiconductor, optoelectronics, data storage, display, MEMS, and optical coating industries. SCI will be integrated into the BSI Nanocustomer relationships.
12
The components and fair value allocation of the consideration transferred in connection with the acquisition are as follows (dollars(in millions):
Consideration Transferred: |
|
|
| |
Cash paid |
| $ | 52.1 |
|
Cash acquired |
|
| (16.0 | ) |
Fair value of hybrid financial instrument - founders |
|
| 20.9 |
|
Fair value of redeemable noncontrolling interest - other shareholders |
|
| 6.8 |
|
Total consideration transferred |
| $ | 63.8 |
|
Allocation of Consideration Transferred: |
|
|
| |
Accounts receivable |
| $ | 0.4 |
|
Inventories |
|
| 0.6 |
|
Other current assets |
|
| 0.7 |
|
Property, plant and equipment |
|
| 1.3 |
|
Other assets |
|
| 0.4 |
|
Intangible assets: |
|
|
| |
Technology |
|
| 12.5 |
|
Customer relationships |
|
| 6.9 |
|
Trade name |
|
| 1.9 |
|
Goodwill |
|
| 47.0 |
|
Liabilities assumed |
|
| (7.9 | ) |
Total consideration allocated |
| $ | 63.8 |
|
Optimal Industrial Automation and Technologies
The Company completed a share purchase agreement to acquire 100% of the outstanding stock of Optimal Industrial Technologies Limited ("OIT") and Optimal Industrial Automation Limited ("OIA"), collectively, "Optimal". The purchase price for the outstanding shares of Optimal was approximately GBP 30.7 million (approximately $40.3 million) with the potential for additional contingent consideration of up to GBP 3.4 million (approximately $4.5 million). Optimal is located in millions):
Consideration Transferred: | ||||
Cash paid | $ | 28.0 | ||
Fair value of contingent consideration | 1.0 | |||
Working capital adjustment | (1.0 | ) | ||
Total consideration transferred | $ | 28.0 | ||
Allocation of Consideration Transferred: | ||||
Inventories | $ | 1.0 | ||
Other current and non-current assets | 1.0 | |||
Intangible assets: | ||||
Technology | 7.1 | |||
Customer relationships | 6.4 | |||
Trade name | 0.4 | |||
Backlog | 1.2 | |||
Goodwill | 12.6 | |||
Liabilities assumed | (1.7 | ) | ||
Total consideration allocated | $ | 28.0 | ||
The preliminary fair value allocation for Optimal included contingent consideration in the amount of $1.0GBP 0.3 million (approximately $0.4 million), which represented the estimated fair value of future payments to the former shareholders of SCIOptimal based on achieving revenue and gross margin targets for the calendar years 2022 and 2023.in 2022. The Company expects to complete the fair value allocation during the measurement period. The amortization period for the intangible assets acquired is ten years for the trade nametechnology, twelve years and technology, and ninefourteen years for the customer relationships.relationships, and thirteen years for the trade names. The Company expects to amortize backlog intangible asset is expected to be fully amortized by December 31, 2021.
13
The components and fair value allocation of the consideration transferred in connection with the acquisition are as follows (in millions):
|
|
|
| |
Consideration Transferred: |
|
|
| |
Cash paid |
| $ | 40.3 |
|
Cash acquired |
|
| (6.2 | ) |
Fair value of contingent consideration |
|
| 0.4 |
|
Total consideration transferred |
| $ | 34.5 |
|
Allocation of Consideration Transferred: |
|
|
| |
Accounts receivable |
| $ | 1.9 |
|
Other current assets |
|
| 0.8 |
|
Property, plant and equipment |
|
| 0.1 |
|
Other assets |
|
| 0.8 |
|
Intangible assets: |
|
|
| |
Technology |
|
| 5.9 |
|
Customer relationships |
|
| 12.9 |
|
Backlog |
|
| 1.1 |
|
Trade name |
|
| 1.2 |
|
Goodwill |
|
| 18.6 |
|
Liabilities assumed |
|
| (8.8 | ) |
Total consideration allocated |
| $ | 34.5 |
|
In addition to the SCI acquisition, in 2021six months ended June 30, 2022, the Company completed various other acquisitions accounted for under the acquisition method that complemented the Company’s existing product offerings. The following table reflects the consideration transferred and the respective reportablereporting segment for the acquisitions (in millions):
Name of Acquisition | Date Acquired | Segment | Total Consideration | Cash Consideration | ||||||||||||
Creative Instruments | July 1, 2021 | BSI Life Science | $ | 1.0 | $ | 1.0 | ||||||||||
SVXR, Inc. | September 9, 2021 | BSI Nano | 14.0 | 11.9 | ||||||||||||
| $ | 15.0 | $ | 12.9 | |||||||||||||
Name of Acquisition |
| Date Acquired |
| Segment |
| Total |
|
| Cash |
| ||
Prolab Instruments GmbH |
| January 17, 2022 |
| BSI Life Science |
| $ | 5.7 |
|
| $ | 5.5 |
|
PepSep Holding ApS |
| February 1, 2022 |
| BSI Life Science |
|
| 4.1 |
|
|
| 2.8 |
|
IonSense, Inc |
| April 5, 2022 |
| BSI Life Science |
|
| 9.5 |
|
|
| 8.1 |
|
|
|
|
|
|
| $ | 19.3 |
|
| $ | 16.4 |
|
In addition to the acquisitions noted above, in the ninesix months ended SeptemberJune 30, 2021,2022, the Company madecompleted minority investments in businesses complementary to its own portfolio.that complemented the Company's existing product offerings. The following table reflects the consideration transferred and the respective reporting segment for thesethe investments (in millions):
Name |
| Acquisition / |
| Date Acquired |
| Segment |
| Total |
|
| Cash |
| ||
PrognomiQ, Inc |
| Investment |
| February 16, 2022 |
| BSI Life Science |
| $ | 12.0 |
|
| $ | 12.0 |
|
Acuamark Diagnostics, Inc |
| Investment |
| April 1, 2022 |
| BSI Life Science |
|
| 2.0 |
|
|
| 2.0 |
|
Ambergen, Inc |
| Investment |
| April 7, 2022 |
| BSI Life Science |
|
| 5.0 |
|
|
| 5.0 |
|
Tofwerk, AG |
| Investment |
| April 28, 2022 |
| BSI Life Science |
|
| 18.6 |
|
|
| 18.6 |
|
|
|
|
|
|
|
|
| $ | 37.6 |
|
| $ | 37.6 |
|
14
Name | Acquisition / Investment | Date Acquired | Segment | Consideration | Cash Consideration | |||||||||||||||
Glycopath Inc. | Investment | February 18, 2021 | BSI Life Science | $ | 2.0 | $ | 2.0 | |||||||||||||
IonPath Inc. | Investment | March 18, 2021 | BSI Life Science | 2.0 | 2.0 | |||||||||||||||
Olaris, Inc. | Investment | September 23, 2021 | BSI Life Science | 0.5 | 0.5 | |||||||||||||||
| $ | 4.5 | $ | 4.5 | |||||||||||||||||
Inventories consisted of the following (dollars in(in millions):
|
| June 30, |
|
| December 31, |
| ||
Raw materials |
| $ | 259.2 |
|
| $ | 218.7 |
|
Work-in-process |
|
| 271.4 |
|
|
| 254.9 |
|
Finished goods |
|
| 140.2 |
|
|
| 144.9 |
|
Demonstration units |
|
| 88.2 |
|
|
| 91.6 |
|
Total Inventories |
| $ | 759.0 |
|
| $ | 710.1 |
|
September 30, 2021 | December 31, 2020 | |||||||
Raw materials | $ | 209.9 | $ | 198.8 | ||||
Work-in-process | 272.5 | 245.7 | ||||||
Finished goods | 155.9 | 152.1 | ||||||
Demonstration units | 94.5 | 95.7 | ||||||
Inventories | $ | 732.8 | $ | 692.3 | ||||
Finished goods include that have been shipped to the Company’s customers for which control has not passed to the customers. As of SeptemberJune 30, 2021,2022, and December 31, 2020,2021, the value of$53.9$51.6 million and $67.8$49.5 million, respectively.
Goodwill
The following table sets forth the changes in the carrying amount of goodwill (dollars in(in millions):
|
| Total |
| |
Balance at December 31, 2021 |
| $ | 339.5 |
|
Current period additions/adjustments |
|
| 74.7 |
|
Foreign currency effect |
|
| (18.0 | ) |
Balance at June 30, 2022 |
| $ | 396.2 |
|
Total | ||||
Balance at December 31, 2020 | $ | 320.4 | ||
Current period additions/adjustments | 12.7 | |||
Foreign currency impact | (8.9 | ) | ||
Balance at September 30, 2021 | $ | 324.2 | ||
Intangible Assets
The following is a summary of intangible assets excluding goodwill (dollars in(in millions):
|
| June 30, 2022 |
|
| December 31, 2021 |
| ||||||||||||||||||
|
| Gross |
|
| Accumulated |
|
| Net Carrying |
|
| Gross |
|
| Accumulated |
|
| Net Carrying |
| ||||||
Existing technology and related patents |
| $ | 324.8 |
|
| $ | (210.2 | ) |
| $ | 114.6 |
|
| $ | 310.4 |
|
| $ | (206.8 | ) |
| $ | 103.6 |
|
Customer relationships |
|
| 169.4 |
|
|
| (63.3 | ) |
|
| 106.1 |
|
|
| 156.1 |
|
|
| (58.2 | ) |
|
| 97.9 |
|
Trade names |
|
| 18.4 |
|
|
| (6.4 | ) |
|
| 12.0 |
|
|
| 15.5 |
|
|
| (5.8 | ) |
|
| 9.7 |
|
Other |
|
| 2.3 |
|
|
| (1.5 | ) |
|
| 0.8 |
|
|
| 1.8 |
|
|
| (1.2 | ) |
|
| 0.6 |
|
Intangible assets |
| $ | 514.9 |
|
| $ | (281.4 | ) |
| $ | 233.5 |
|
| $ | 483.8 |
|
| $ | (272.0 | ) |
| $ | 211.8 |
|
September 30, 2021 | December 31, 2020 | |||||||||||||||||||||||
Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | |||||||||||||||||||
Existing technology and related patents | $ | 308.4 | $ | (202.1 | ) | $ | 106.3 | $ | 309.8 | $ | (194.6 | ) | $ | 115.2 | ||||||||||
Customer relationships | 155.1 | (54.6 | ) | 100.5 | 148.3 | (45.4 | ) | 102.9 | ||||||||||||||||
Trade names | 15.1 | (5.4 | ) | 9.7 | 15.2 | (4.4 | ) | 10.8 | ||||||||||||||||
Other | 1.8 | (0.6 | ) | 1.2 | 0.3 | (0.1 | ) | 0.2 | ||||||||||||||||
Intangible assets | $ | 480.4 | $ | (262.7 | ) | $ | 217.7 | $ | 473.6 | $ | (244.5 | ) | $ | 229.1 | ||||||||||
For the three months ended SeptemberJune 30, 20212022 and 2020,2021, the Company recorded amortization expense of $9.3$9.4 million and $9.0$9.1 million, respectively, related to intangible assets subject to amortization. For the ninesix months ended SeptemberJune 30, 20212022 and 2020,2021, the Company recorded amortization expense of $27.3$18.6 million and $26.7$18.0 million, respectively, related to intangible assets subject to amortization.
On a quarterly basis, the Company reviews its intangible assets to determine if there have been any events that could indicate an impairment. There were 0 events noted for the six months ended June 30, 2022 or 2021.
15
The Company’s debt obligations consistedconsist of the following (dollars in(in millions):
|
| June 30, |
|
| December 31, |
| ||
EUR notes (in U.S. dollars) under the 2021 Note Purchase Agreement |
| $ | 157.3 |
|
| $ | 170.7 |
|
CHF notes (in U.S. dollars) under the 2021 Note Purchase Agreement |
|
| 314.5 |
|
|
| 329.2 |
|
CHF notes (in U.S. dollars) under the 2019 Note Purchase Agreement |
|
| 311.4 |
|
|
| 325.9 |
|
U.S. Dollar notes under the 2019 Term Loan |
|
| 297.8 |
|
|
| 299.2 |
|
U.S. Dollar notes under the 2012 Note Purchase Agreement |
|
| 100.0 |
|
|
| 205.0 |
|
Unamortized debt issuance costs |
|
| (1.8 | ) |
|
| (2.0 | ) |
Other loans |
|
| 1.8 |
|
|
| 1.9 |
|
Total notes and loans outstanding |
|
| 1,181.0 |
|
|
| 1,329.9 |
|
Finance lease obligations |
|
| 4.0 |
|
|
| 4.3 |
|
Total debt |
|
| 1,185.0 |
|
|
| 1,334.2 |
|
Current portion of long-term debt |
|
| (14.0 | ) |
|
| (112.4 | ) |
Total long-term debt, less current portion |
| $ | 1,171.0 |
|
| $ | 1,221.8 |
|
September 30, 2021 | December 31, 2020 | |||||||
US Dollar notes under the 2012 Note Purchase Agreement | $ | 205.0 | $ | 205.0 | ||||
CHF notes (in dollars) under the 2019 Note Purchase Agreement | 318.1 | 335.5 | ||||||
US Dollar notes under the 2019 Term Loan | 300.0 | 300.0 | ||||||
Unamortized debt issuance costs | (2.1 | ) | (2.4 | ) | ||||
Finance lease obligations and other loans | 6.0 | 6.4 | ||||||
Total debt | 827.0 | 844.5 | ||||||
Current portion of long-term debt | (109.5 | ) | (2.2 | ) | ||||
Total long-term debt, less current portion | $ | 717.5 | $ | 842.3 | ||||
The following is a summary of the maximum commitments and the net amounts available to the Company under its credit agreementsthe 2019 Revolving Credit Agreement and other lines of credit with various financial institutions located primarily in Germany and Switzerland that are unsecured and typically due upon demand with interest payable monthly, at SeptemberJune 30, 20212022 (in millions):
|
| Weighted |
|
| Total Amount |
|
| Outstanding |
|
| Outstanding |
|
| Total |
| |||||
2019 Credit Agreement |
|
| 1.3 | % |
| $ | 600.0 |
|
| $ | — |
|
| $ | 0.1 |
|
| $ | 599.9 |
|
Bank guarantees and working capital line |
| varies |
|
|
| 108.7 |
|
|
| — |
|
|
| 108.7 |
|
|
| — |
| |
Total revolving lines of credit |
|
|
|
| $ | 708.7 |
|
| $ | — |
|
| $ | 108.8 |
|
| $ | 599.9 |
| |
Weighted Average Interest Rate | Total Amount Committed by Lenders | Outstanding Borrowings | Outstanding Letters of Credit | Total Amount Available | ||||||||||||||||
2019 Credit Agreement | 1.3 | % | $ | 600.0 | $ | — | $ | 0.1 | $ | 599.9 | ||||||||||
Bank guarantees and working capital line | varies | 115.2 | — | 115.2 | — | |||||||||||||||
Total revolving lines of credit | $ | 715.2 | $ | — | $ | 115.3 | $ | 599.9 | ||||||||||||
As of SeptemberJune 30, 2021,2022, the Company was in compliance with the financial covenants of all debt agreements.
As of 16SeptemberJune 30, 2021,2022, the Company had several cross-currency and interest rate swap agreements with a notional value of $150.0$148.9 million of U.S. to Swiss Franc and a notional value of $355.0$248.9 million of U.S. to Euro to hedge the variability in the movement of foreign currency exchange rates on portions of our Euro and Swiss Franc denominated net asset investments. These agreements qualify for hedge accounting and accordingly the changes in fair value of the derivative are recorded in other comprehensive income as part of foreign currency translation adjustments and remain in accumulated comprehensive income (loss) attributable to Bruker Corporation in shareholders’ equity until the sale or substantial liquidation of the foreign operation. The difference between the interest rate received and paid under the interest rate and cross-currency swap agreements is recorded in interest and other income (expenses) in the consolidated statements of income and comprehensive income. As a result of entering into these agreements, the Company lowered net interest expense by1.41.6 million and $1.3 million duringeach of SeptemberJune 30, 2022 and 2021, and 2020,respectively, and by $4.1 million and$5.82.7 million during both the ninesix months ended SeptemberJune 30, 20212022 and 2020,2021, respectively. The Company presents the cross-currency swap periodic settlements in investing activities and the interest rate swap periodic settlements in operating activities in the statement of cash flows.14
The Company measures the following financial assets and liabilities at fair value on a recurring basis. The following tables set forth the Company’s financial instruments measured at fair value on a recurring basis and present them within the fair value hierarchy using the lowest level of input that is significant to the fair value measurement (dollars in(in millions):
June 30, 2022 |
| Total |
|
| Quoted Prices |
|
| Significant |
|
| Significant |
| ||||
Assets: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Time deposits and money market funds |
| $ | 192.8 |
|
| $ | 80.0 |
|
| $ | 112.8 |
|
| $ | — |
|
Interest rate and cross-currency swap agreements |
|
| 32.6 |
|
|
| — |
|
|
| 32.6 |
|
|
| — |
|
Forward currency contracts |
|
| 0.3 |
|
|
| — |
|
|
| 0.3 |
|
|
| — |
|
Embedded derivatives in purchase and delivery contracts |
|
| 0.2 |
|
|
| — |
|
|
| 0.2 |
|
|
| — |
|
Debt securities available for sale |
|
| 1.2 |
|
|
| — |
|
|
| 0 |
|
|
| 1.2 |
|
Total assets recorded at fair value |
| $ | 227.1 |
|
| $ | 80.0 |
|
| $ | 145.9 |
|
| $ | 1.2 |
|
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Contingent consideration |
| $ | 6.5 |
|
| $ | — |
|
| $ | 0 |
|
| $ | 6.5 |
|
Hybrid instruments liability |
|
| 32.1 |
|
|
| — |
|
|
| 0 |
|
|
| 32.1 |
|
Interest rate and cross-currency swap agreements |
|
| 7.3 |
|
|
| — |
|
|
| 7.3 |
|
|
| 0 |
|
Forward currency contracts |
|
| 0.4 |
|
|
| — |
|
|
| 0.4 |
|
|
| 0 |
|
Fixed price commodity contracts |
|
| 1.0 |
|
|
| — |
|
|
| 1.0 |
|
|
| 0 |
|
Long-term fixed interest rate debt |
|
| 763.4 |
|
|
| — |
|
|
| 763.4 |
|
|
| 0 |
|
Total liabilities recorded at fair value |
| $ | 810.7 |
|
| $ | — |
|
| $ | 772.1 |
|
| $ | 38.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
December 31, 2021 |
| Total |
|
| Quoted Prices |
|
| Significant |
|
| Significant |
| ||||
Assets: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Time deposits and money market funds |
| $ | 367.7 |
|
| $ | — |
|
| $ | 367.7 |
|
| $ | — |
|
Short-term investments |
|
| 100.0 |
|
|
| — |
|
|
| 100.0 |
|
|
| — |
|
Interest rate and cross-currency swap agreements |
|
| 6.4 |
|
|
| — |
|
|
| 6.4 |
|
|
| — |
|
Forward currency contracts |
|
| 0.7 |
|
|
| — |
|
|
| 0.7 |
|
|
| — |
|
Embedded derivatives in purchase and delivery contracts |
|
| 0.2 |
|
|
| — |
|
|
| 0.2 |
|
|
| — |
|
Fixed price commodity contracts |
|
| 0.4 |
|
|
| — |
|
|
| 0.4 |
|
|
| — |
|
Debt securities available for sale |
|
| 1.2 |
|
|
| — |
|
|
| 0 |
|
|
| 1.2 |
|
Total assets recorded at fair value |
| $ | 476.6 |
|
| $ | — |
|
| $ | 475.4 |
|
| $ | 1.2 |
|
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Contingent consideration |
| $ | 6.6 |
|
| $ | — |
|
| $ | 0 |
|
| $ | 6.6 |
|
Hybrid instruments liability |
|
| 15.6 |
|
|
| — |
|
|
| 0 |
|
|
| 15.6 |
|
Interest rate and cross-currency swap agreements |
|
| 23.9 |
|
|
| — |
|
|
| 23.9 |
|
|
| 0 |
|
Forward currency contracts |
|
| 0.3 |
|
|
| — |
|
|
| 0.3 |
|
|
| 0 |
|
Long-term fixed interest rate debt |
|
| 1,043.3 |
|
|
| — |
|
|
| 1,043.3 |
|
|
| 0 |
|
Total liabilities recorded at fair value |
| $ | 1,089.7 |
|
| $ | — |
|
| $ | 1,067.5 |
|
| $ | 22.2 |
|
September 30, 2021 | Total | Quoted Prices in Active Markets Available (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | ||||||||||||
Assets: | ||||||||||||||||
Time deposits and money market funds | $ | 12.4 | $ | — | $ | 12.4 | $ | — | ||||||||
Short-term investments | 96.8 | — | 96.8 | — | ||||||||||||
Interest rate and cross currency swap agreements | 7.1 | — | 7.1 | — | ||||||||||||
Fixed price commodity contracts | 0.8 | — | 0.8 | — | ||||||||||||
Debt securities available for sale | 1.2 | — | — | 1.2 | ||||||||||||
Total assets recorded at fair value | $ | 118.3 | $ | — | $ | 117.1 | $ | 1.2 | ||||||||
Liabilities: | ||||||||||||||||
Contingent consideration | $ | 5.6 | $ | — | $ | — | $ | 5.6 | ||||||||
Hybrid instrument liability | 14.3 | — | — | 14.3 | ||||||||||||
Interest rate and cross currency swap agreements | 29.0 | — | 29.0 | — | ||||||||||||
Embedded derivatives in purchase and delivery contracts | 0.1 | — | 0.1 | — | ||||||||||||
Forward currency contracts | 0.7 | — | 0.7 | — | ||||||||||||
Long-term fixed interest rate debt | 535.1 | — | 535.1 | — | ||||||||||||
Total liabilities recorded at fair value | $ | 584.8 | $ | — | $ | 564.9 | $ | 19.9 | ||||||||
December 31, 2020 | Total | Quoted Prices in Active Markets Available (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | ||||||||||||
Assets: | ||||||||||||||||
Time deposits and money market funds | $ | 183.2 | $ | — | $ | 183.2 | $ | — | ||||||||
Short-term investments | 50.0 | — | 50.0 | — | ||||||||||||
Interest rate and cross currency swap agreements | 7.6 | — | 7.6 | — | ||||||||||||
Forward currency contracts | 2.1 | — | 2.1 | — | ||||||||||||
Embedded derivatives in purchase and delivery contracts | 0.1 | — | 0.1 | — | ||||||||||||
Fixed price commodity contracts | 3.1 | — | 3.1 | — | ||||||||||||
Debt securities available for sale | 1.2 | — | — | 1.2 | ||||||||||||
Total assets recorded at fair value | $ | 247.3 | $ | — | $ | 246.1 | $ | 1.2 | ||||||||
Liabilities: | ||||||||||||||||
Contingent consideration | $ | 4.3 | $ | — | $ | — | $ | 4.3 | ||||||||
Hybrid instrument liability | 13.9 | — | — | 13.9 | ||||||||||||
Interest rate and cross currency swap agreements | 61.5 | — | 61.5 | — | ||||||||||||
Forward currency contracts | 0.4 | — | 0.4 | — | ||||||||||||
Long-term fixed interest rate debt | 549.8 | — | 549.8 | — | ||||||||||||
Total liabilities recorded at fair value | $ | 629.9 | $ | — | $ | 611.7 | $ | 18.2 | ||||||||
Derivative financial instruments consist primarily of cash equivalents, short-term investments, restricted cash,are classified within level 2 because there is not an active market for each derivative instruments consisting of forward foreign exchange contracts, cross-currency interest rate swap agreements, commodity contracts, derivatives embedded in certain purchase and sale contracts, derivatives embedded within noncontrolling interests, accounts receivable, accounts payable, contingent consideration and long-term debt. The carrying amountscontract. However, the inputs used to calculate the value of the Company’s cash equivalents, short-term investments and restricted cash, accounts receivable, borrowings under a revolving credit agreement and accounts payable approximate fair value because of their short-term nature. Derivative assets and liabilitiesinstruments are measured at fair value on a recurring basis. The Company’s long-term debt consists principally of a note purchase agreement entered into in 2012 and a revolving credit agreement, long term loan agreement and note purchase agreement entered into in 2019.
The Company measures certain assets and liabilities at fair value with changes in fair value recognized in earnings. Fair value treatment may be elected either upon initial recognition of an eligible asset or liability or, for an existing asset or liability, if an event triggers a new basis of accounting. The Company did not elect to remeasure any of its existing financial assets or liabilities and did not elect the fair value option for any financial assets or liabilities which originated during the ninesix months ended SeptemberJune 30, 20212022 or 2020.
The fair value of the long-term fixed interest rate debt, which has been classified as Level 2, was based on market and observable sources with similar maturity dates. The carrying value of ourthe Company's variable rate debt approximates its fair value at SeptemberJune 30, 20212022 and December 31, 2020.
17
On a quarterly basis, the Company reviews its short-term investments to determine if there have been any events that could createindicate an impairment. NoneThere were none noted for the ninesix months ended SeptemberJune 30, 20212022 or 2020.
Debt securities consist of investments in redeemable preferred stock. Debt securities are classified as either current or long-term investments based on their contractual maturities unless the Company intends to sell an investment within the next twelve months, in which case it is classified as current on the consolidated balance sheets. Debt securities are classified as available for sale and are carried at fair value.
Contingent consideration recorded within other current and other long-term liabilities represents the estimated fair value of future payments to the former shareholders as part of certain acquisitions. The contingent consideration is primarily based on the applicable acquired company achieving annual revenue and gross margin targets in certain years as specified in the relevant purchase and sale agreement. The Company initially values the contingent consideration on the acquisition date by using a Monte Carlo simulation or an income approach method. The Monte Carlo method models future revenue and costs of goods sold projections and discounts the average results to present value. The income approach method involves calculating the earnout payment based on the forecasted cash flows, adjusting the future earnout payment for the risk of reaching the projected financials, and then discounting the future payments to present value by the counterparty risk. The counterparty risk considers the risk of the buyer having the cash to make the earnout payments and is commensurate with a cost of debt over an appropriate term.
The following table sets forth the changes in contingent consideration liabilities (dollars in(in millions):
|
| Total |
| |
Balance at December 31, 2021 |
| $ | 6.6 |
|
Current period additions |
|
| 3.1 |
|
Current period adjustments |
|
| 1.9 |
|
Current period settlements |
|
| (4.8 | ) |
Foreign currency effect |
|
| (0.3 | ) |
Balance at June 30, 2022 |
| $ | 6.5 |
|
Balance at December 31, 2020 | $ | 4.3 | ||
Current period additions | 1.9 | |||
Current period adjustments | (0.1 | ) | ||
Current period settlements | (0.4 | ) | ||
Foreign currency effect | (0.1 | ) | ||
Balance at September 30, 2021 | $ | 5.6 | ||
As part of the 2018 Mestrelab Research, S.L. (“Mestrelab”("Mestrelab") acquisition,and 2022 PreOmics GmbH acquisitions, the Company entered into an agreementagreements with the noncontrolling interest holders that providesprovide the Company with the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining 49% of Mestrelabownerships for cash at a contractually defined redemption value.values. These rights (an embedded derivative) are exercisable beginning in 2022 and(embedded derivatives) can be accelerated, at a discounted redemption value,values, upon certain events related to post combination services. As the option isoptions are tied to continued employment, the Company classified the hybrid instrumentinstruments (noncontrolling interestinterests with an embedded derivative)derivatives) as a long-term liabilityliabilities on the consolidated balance sheet. Subsequent to the acquisition,acquisitions, the carrying value of the hybrid instrument isinstruments are remeasured to fair value with changes recorded to stock-based compensation expense in proportion to the respective requisite service period vested. The Company classified the hybrid instrument is classifiedinstruments as Level 3 in the fair value hierarchy.
The following table sets forth the changes in hybrid instrumentinstruments liability (dollars in(in millions):
|
| Total |
| |
Balance at December 31, 2021 |
| $ | 15.6 |
|
Current period additions |
|
| 20.4 |
|
Current period adjustments |
|
| 10.1 |
|
Current period settlements |
|
| (11.6 | ) |
Foreign currency effect |
|
| (2.4 | ) |
Balance at June 30, 2022 |
| $ | 32.1 |
|
18
Balance at December 31, 2020 | $ | 13.9 | ||
Current period adjustments | 1.1 | |||
Foreign currency effect | (0.7 | ) | ||
Balance at September 30, 2021 | $ | 14.3 | ||
Commodity Price Risk Management
The Company has arrangements with certain customers under which it has a firm commitment to deliver copper-based superconductors at a fixed price. In order to minimize the volatility that fluctuations in the price of copper have on the Company’s sales of these commodities, the Company had fixed priceenters into commodity contracts with notional amounts aggregating $4.5 million and $8.8 million, respectively.hedge contracts. As commodity contracts settle, gains (losses) as aresult of changes in fair values are adjusted to the contracts with the customers through revenue.
Foreign Exchange Rate Risk Management
The Company had the following notional amounts outstanding under forward currencyforeign exchange contracts, and cross-currency interest rate swap agreements and long-term debt designated as net investment hedges (in millions) and the respective fair value of (dollarsthe instruments recorded in the consolidated balance sheets as follows (in millions):
|
| June 30, 2022 |
|
| December 31, 2021 |
| ||||||||||
|
| Notional (in USD) |
|
| Fair Value |
|
| Notional (in USD) |
|
| Fair Value |
| ||||
Derivatives designated as hedging instruments |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Interest rate cross-currency swap agreements |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Other current assets |
|
|
|
| $ | 10.6 |
|
|
|
|
| $ | 6.4 |
| ||
Other assets |
|
|
|
|
| 22.0 |
|
|
|
|
|
| 0 |
| ||
Other current liabilities |
|
|
|
|
| 0 |
|
|
|
|
|
| (5.8 | ) | ||
Other long-term liabilities |
|
|
|
|
| (7.3 | ) |
|
|
|
|
| (18.1 | ) | ||
|
| $ | 397.8 |
|
| $ | 25.3 |
|
| $ | 504.3 |
|
| $ | (17.5 | ) |
Long-term debt |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Long-term debt |
|
| 783.2 |
|
|
| 7.4 |
|
|
| 825.8 |
|
|
| (35.1 | ) |
Total derivatives designated as hedging instruments |
| $ | 1,181.0 |
|
| $ | 32.7 |
|
| $ | 1,330.1 |
|
| $ | (52.6 | ) |
Derivatives not designated as hedging instruments |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Forward currency contracts |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Other current assets |
| $ | 26.7 |
|
| $ | 0.3 |
|
| $ | 157.7 |
|
| $ | 0.7 |
|
Other current liabilities |
|
| 103.6 |
|
|
| (0.4 | ) |
|
| 23.0 |
|
|
| (0.3 | ) |
Embedded derivatives in purchase and delivery contracts |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Other current assets |
|
| 11.0 |
|
|
| 0.2 |
|
|
| 8.5 |
|
|
| 0.2 |
|
Fixed price commodity contracts |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Other current assets |
|
| 0 |
|
|
| 0 |
|
|
| 5.5 |
|
|
| 0.4 |
|
Other current liabilities |
|
| 9.0 |
|
|
| (1.0 | ) |
|
| 0 |
|
|
| 0 |
|
Total derivatives not designated as hedging instruments |
| $ | 150.3 |
|
| $ | (0.9 | ) |
| $ | 194.7 |
|
| $ | 1.0 |
|
Total derivatives |
| $ | 1,331.3 |
|
| $ | 31.8 |
|
| $ | 1,524.8 |
|
| $ | (51.6 | ) |
September 30, 2021 | December 31, 2020 | |||||||||||||||
Notional Amount in U.S. Dollars | Fair Value | Notional Amount in U.S. Dollars | Fair Value | |||||||||||||
Forward currency contracts (1): | ||||||||||||||||
Assets | $ | 10.4 | $ | — | $ | 175.8 | $ | 2.1 | ||||||||
Liabilities | 114.1 | (0.7 | ) | 102.5 | (0.4 | ) | ||||||||||
Cross-currency and interest rate swap agreements (2): | ||||||||||||||||
Liabilities | 505.0 | (21.9 | ) | 505.0 | (53.9 | ) | ||||||||||
Long-term debt | ||||||||||||||||
Liabilities | 318.1 | (20.2 | ) | 335.5 | (37.6 | ) | ||||||||||
Total | $ | 947.6 | $ | (42.8 | ) | $ | 1,118.8 | $ | (89.8 | ) | ||||||
In addition, the Company periodically enters into purchase and sales contracts denominated in currencies other than the functional currency of the parties to the transaction. The Company accounts for these transactions separately valuing the “embedded derivative” component of these contracts. The contracts, denominated in currencies other than the functional currency of the transacting parties, amounted to $6.0$11.0 million for the delivery of products and $7.0$8.5 million for the purchase of products at SeptemberJune 30, 20212022 and $7.5 million for the delivery of products and $4.8 million for the purchase of products at December 31, 2020.2021, respectively. The Company records the changes in the fair value of these embedded derivatives are recorded in interest and other income (expense), net in the consolidated statements of income and comprehensive income.
19
September 30, 2021 | December 31, 2020 | |||||||
Derivatives designated as hedging instruments | ||||||||
Interest rate cross-currency swap agreements | ||||||||
Other current assets | $ | 7.1 | $ | 7.6 | ||||
Other current liabilities | (8.5 | ) | (4.3 | ) | ||||
Other long-term liabilities | (20.5 | ) | (57.2 | ) | ||||
| (21.9 | ) | (53.9 | ) | |||||
Long-term debt | ||||||||
Long-term debt | (20.2 | ) | (37.6 | ) | ||||
Total derivatives designated as hedging instruments | $ | (42.1 | ) | $ | (91.5 | ) | ||
Derivatives not designated as hedging instruments | ||||||||
Forward currency contracts | ||||||||
Other current assets | $ | — | $ | 2.1 | ||||
Other current liabilities | (0.7 | ) | (0.4 | ) | ||||
Embedded derivatives in purchase and delivery contracts | ||||||||
Other current assets | — | 0.1 | ||||||
Other current liabilities | (0.1 | ) | — | |||||
Fixed price commodity contracts | ||||||||
Other current assets | 0.8 | 3.1 | ||||||
Total derivatives not designated as hedging instruments | 0 | 4.9 | ||||||
Total derivatives | $ | (42.1 | ) | $ | (86.6 | ) | ||
The following is a summary of the activitygain (loss) included in the unaudited condensed consolidated statements of income and comprehensive income related to the derivative instruments described above (in millions):
|
|
|
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| ||||||||||
|
| Financial Statement Classification |
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
Derivatives not designated as hedging instruments |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Forward currency contracts |
| Interest and other income (expense), net |
| $ | (2.6 | ) |
| $ | 1.1 |
|
| $ | (4.1 | ) |
| $ | (3.9 | ) |
Embedded derivatives in purchase and delivery contracts |
| Interest and other income (expense), net |
|
| 0.1 |
|
|
| 0 |
|
|
| 0 |
|
|
| (0.4 | ) |
|
|
|
|
| (2.5 | ) |
|
| 1.1 |
|
|
| (4.1 | ) |
|
| (4.3 | ) |
Derivatives designated as cash flow hedging instruments |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Interest rate cross-currency swap agreements |
| Interest and other income (expense), net |
| $ | (0.6 | ) |
| $ | (1.2 | ) |
| $ | (1.6 | ) |
| $ | (2.3 | ) |
Derivatives designated as net investment hedging instruments |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Interest rate cross-currency swap agreements |
| Interest and other income (expense), net |
|
| 2.2 |
|
|
| 2.5 |
|
|
| 4.3 |
|
|
| 5.0 |
|
|
|
|
|
| 1.6 |
|
|
| 1.3 |
|
|
| 2.7 |
|
|
| 2.7 |
|
Total |
|
|
| $ | (0.9 | ) |
| $ | 2.4 |
|
| $ | (1.4 | ) |
| $ | (1.6 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| ||||||||||
|
| Financial Statement Classification |
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
Derivatives designated as cash flow hedging instruments |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Interest rate cross-currency swap agreements |
| Accumulated other comprehensive income, net of tax |
| $ | 3.7 |
|
| $ | 0.7 |
|
| $ | 15.1 |
|
| $ | 10.6 |
|
|
|
|
|
| 3.7 |
|
|
| 0.7 |
|
|
| 15.1 |
|
|
| 10.6 |
|
Derivatives designated as net investment hedging instruments |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Interest rate cross-currency swap agreements |
| Accumulated other comprehensive income, net of tax |
| $ | 14.3 |
|
| $ | 0.4 |
|
| $ | 15.0 |
|
| $ | 18.2 |
|
Long-term debt |
| Accumulated other comprehensive income, net of tax |
|
| 23.5 |
|
|
| (0.7 | ) |
|
| 32.5 |
|
|
| 20.0 |
|
|
|
|
|
| 37.8 |
|
|
| (0.3 | ) |
|
| 47.5 |
|
|
| 38.2 |
|
Total |
|
|
| $ | 41.5 |
|
| $ | 0.4 |
|
| $ | 62.6 |
|
| $ | 48.8 |
|
Location of gain (loss) recognized in income on derivative | ||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||||
Derivatives not designated as hedging instruments | ||||||||||||||||||
Forward currency contracts | Interest and other income (expense), net | $ | (0.9 | ) | $ | (0.2 | ) | $ | (4.8 | ) | $ | (0.4 | ) | |||||
Embedded and delivery contracts | Interest and other income (expense), net | 0.1 | (0.1 | ) | (0.3 | ) | 0.8 | |||||||||||
| (0.8 | ) | (0.3 | ) | (5.1 | ) | 0.4 | ||||||||||||
Derivatives designated as cash flow hedging instruments | ||||||||||||||||||
Interest rate cross-currency swap agreements | Interest and other income (expense), net | $ | (1.2 | ) | $ | (1.1 | ) | $ | (3.5 | ) | $ | (1.9 | ) | |||||
Derivatives designated as net investment hedging instruments | ||||||||||||||||||
Interest rate cross-currency swap agreements | Interest and other income (expense), net | 2.6 | 2.5 | 7.6 | 7.7 | |||||||||||||
| 1.4 | 1.4 | 4.1 | 5.8 | |||||||||||||||
Total | $ | 0.6 | $ | 1.1 | $ | (1.0 | ) | $ | 6.2 | |||||||||
Amount of unrealized gain (loss) on contracts recognized in other comprehensive income (loss) | ||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||
Financial Statement Classification | 2021 | 2020 | 2021 | 2020 | ||||||||||||||
Derivatives designated as cash flow hedging instruments | ||||||||||||||||||
Interest rate cross-currency swap agreements | Accumulated other comprehensive income, net of tax | $ | 0.9 | $ | (0.2 | ) | $ | 11.5 | $ | (22.1 | ) | |||||||
$ | 0.9 | $ | (0.2 | ) | $ | 11.5 | $ | (22.1 | ) | |||||||||
Derivatives designated as net investment hedging instruments | ||||||||||||||||||
Interest rate cross-currency swap agreements | Accumulated other comprehensive income, net of tax | $ | 7.4 | $ | (21.9 | ) | $ | 25.6 | $ | (0.3 | ) | |||||||
Long-term debt | Accumulated other comprehensive income, net of tax | 2.2 | (8.2 | ) | 22.2 | (15.3 | ) | |||||||||||
$ | 9.6 | $ | (30.1 | ) | $ | 47.8 | $ | (15.6 | ) | |||||||||
Total | $ | 10.5 | $ | (30.3 | ) | $ | 59.3 | $ | (37.7 | ) | ||||||||
The Company accounts for income taxes using the asset and liability approach by recognizing deferred tax assets and liabilities for the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differencesare expected to be reflected in the tax return. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not tobe realized. In addition, the Company accounts for uncertain tax positions that have reached a minimum recognition threshold.
The income tax provision for the three months ended SeptemberJune 30, 2022 and 2021 and 2020 was $20.7$19.9 million and $20.0$21.3 million, respectively, representing effective tax rates of 19.0%28.6% and 26.6%26.6%, respectively.decreaseincome tax provision for the six months ended June 30, 2022 and 2021 was $51.8 million and $48.8 million, respectively, representing effective tax rates of 31.7% and 29.5%, respectively. The increase in our effective tax rate was primarily due to the jurisdictional profit miximpact of U.S. legislation that became effective as of January 1, 2022 limiting the deductibility of research and development expenses and the benefit relating to foreign tax credits, and impact of favorable discrete items in the period. The income tax provision for the nine months ended September 30, 2021 and 2020 was $69.5 million and $30.0 million, respectively, representing effective tax rates of 25.4% and 25.0%, respectively. The increase in the Company’s effective tax rate was primarily due to the increase in profit before income tax and the jurisdictional profit mix, partially offset by the impact of discrete items in the period.
20
As of SeptemberJune 30, 20212022 and December 31, 2020,2021, the Company had gross unrecognized tax benefits, excluding penalties and interest, of approximately $34.8$49.8 million and $22.7$51.4 million, respectively, which, if recognized, would result in a reduction of the Company’s effective tax rate. The Company recognizes penalties and interest related to unrecognized tax benefits in the provision for income taxes. As of SeptemberJune 30, 20212022 and December 31, 2020,2021, approximately $2.3$3.6 million and $1.8$3.1 million, respectively, of accrued interest and penalties related to uncertain tax positions wasand were included in other long-term liabilities on the Company’s unaudited condensed consolidated balance sheets. Penalties and interest of $0.2 million and $0.1$0.2 million were recorded in the provision for income taxes for unrecognized tax benefits during both of the three months ended SeptemberJune 30, 20212022 and 2020.2021. Penalties and interest of $0.6$0.7 million and $0.4$0.3 million waswere recorded in the provision for income taxes for unrecognized tax benefits during the ninesix months ended SeptemberJune 30, 2022 and 2021, respectively.
The Company has been subject to a tax examination in Germany for the years 2009 through 2012 whereby the German tax authorities had imposed additional tax assessments for those years. Due to the nature of the additional tax assessments, the Company filed for competent authority relief from those assessments under MAP of the United States-Germany income tax treaty. A final resolution has been reached with the respective tax authorities in Germany and 2020, respectively.the United States during the first quarter of 2022 and the liability was paid in the second quarter of 2022.
The Company files tax returns in the United States, which includesinclude federal, state and local jurisdictions, and many foreign jurisdictions with varying statutes of limitations. The Company considers Germany, the United States and Switzerland to be its significant tax jurisdictions. The majority of the Company’s earnings are derived in Germany and Switzerland. Accounting for the various federal and local taxing authorities, the statutory rates for 20212022 are approximately 30.0%30.0% and 20.0%20.0% for Germany and Switzerland, respectively. The mix of earnings in those two jurisdictions resulted in an increase of 5.5%5.3% from the U.S. statutory rate of 21.0%21.0% in the ninesix months ended SeptemberJune 30, 2021.2022.
The following table sets forth the computation of basic and diluted weighted average shares outstanding and net income per common share attributable to Bruker shareholders (dollars in(in millions, except per share amounts):
|
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
Net income attributable to Bruker Corporation |
| $ | 49.5 |
|
| $ | 57.6 |
|
| $ | 111.1 |
|
| $ | 114.3 |
|
Weighted average shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Weighted average shares outstanding-basic |
|
| 149.0 |
|
|
| 151.3 |
|
|
| 149.7 |
|
|
| 151.6 |
|
Effect of dilutive securities: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Stock options and restricted stock units |
|
| 0.8 |
|
|
| 1.6 |
|
|
| 0.9 |
|
|
| 1.4 |
|
|
|
| 149.8 |
|
|
| 152.9 |
|
|
| 150.6 |
|
|
| 153.0 |
|
Net income per common share attributable to Bruker Corporation shareholders: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Basic |
| $ | 0.33 |
|
| $ | 0.38 |
|
| $ | 0.74 |
|
| $ | 0.75 |
|
Diluted |
| $ | 0.33 |
|
| $ | 0.38 |
|
| $ | 0.74 |
|
| $ | 0.75 |
|
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Net income attributable to Bruker Corporation, as reported | $ | 87.1 | $ | 54.3 | $ | 201.4 | $ | 88.9 | ||||||||
Weighted average shares outstanding: | ||||||||||||||||
Weighted average shares outstanding-basic | 151.4 | 153.2 | 151.5 | 153.7 | ||||||||||||
Effect of dilutive securities: | ||||||||||||||||
Stock options and restricted stock awards and units | 1.4 | 1.1 | 1.5 | 1.1 | ||||||||||||
| 152.8 | 154.3 | 153.0 | 154.8 | |||||||||||||
Net income per common share attributable to Bruker Corporation shareholders: Basic | $ | 0.58 | $ | 0.35 | $ | 1.33 | $ | 0.58 | ||||||||
Diluted | $ | 0.57 | $ | 0.35 | $ | 1.32 | $ | 0.57 | ||||||||
The following common share equivalents have been excluded from the computation of diluted weighted-averageweighted average shares outstanding, as their effect would have been anti-dilutive (amounts in millions of shares):
|
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
Stock options |
|
| 0.1 |
|
|
| — |
|
|
| 0.1 |
|
|
| — |
|
Unvested restricted stock units |
|
| 0.2 |
|
|
| — |
|
|
| 0.2 |
|
|
| — |
|
21
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Stock options | 0 | 0.3 | 0 | 0.1 | ||||||||||||
Unvested restricted stock units | 0 | 0.2 | 0 | 0.1 | ||||||||||||
Share Repurchase Program
In May 2019, the Company’s Board of Directors approved a stockshare repurchase plan (the “2019 Repurchase Program”) authorizing the purchase of common stock in the amount of up to $300.0
In May 2021, the Company’s Board of Directors approved a stockshare repurchase plan (the “2021 Repurchase Program”) authorizing the purchase of common stock in the amount of up to $500.0$500.0 million from time to time over atwo-yearninethree months ended SeptemberJune 30, 2021,2022, the Company purchased a total of 530,703983,741 shares at an aggregate cost of $36.6$60.3 million under the 2021 Repurchase Program. NaNDuring the six months ended June 30, 2022, the Company purchased a total of 2,586,796 shares wereat an aggregate cost of $165.9 million under the 2021 Repurchase Program. The Company purchased duringa total of 530,703 shares at an aggregate cost of $36.6 million in the three and six months ended September 30, 2021. At SeptemberJune 30, 2021 $463.4under the 2021 Repurchase Program. At June 30, 2022, $215.3 million remained available for future purchases under the 2021 Repurchase Program.
Accumulated Other Comprehensive Income, (Loss)
The following is a summary of comprehensive income (dollars in(in millions):
|
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
Consolidated net income |
| $ | 49.7 |
|
| $ | 58.7 |
|
| $ | 111.8 |
|
| $ | 116.5 |
|
Foreign currency translation adjustments |
|
| (76.9 | ) |
|
| 14.3 |
|
|
| (107.4 | ) |
|
| (53.6 | ) |
Derivatives designated as hedging instruments, net of tax |
|
| 41.5 |
|
|
| 0.4 |
|
|
| 62.6 |
|
|
| 48.8 |
|
Pension liability adjustments, net of tax |
|
| 1.6 |
|
|
| 0 |
|
|
| 2.1 |
|
|
| 3.3 |
|
Comprehensive income |
|
| 15.9 |
|
|
| 73.4 |
|
|
| 69.1 |
|
|
| 115.0 |
|
Less: Comprehensive income (loss) attributable to noncontrolling interests |
|
| (0.4 | ) |
|
| (0.7 | ) |
|
| (0.2 | ) |
|
| 0.2 |
|
Less: Comprehensive loss attributable to redeemable noncontrolling interests |
|
| (0.5 | ) |
|
| 0 |
|
|
| (0.7 | ) |
|
| 0 |
|
Comprehensive income attributable to Bruker Corporation |
| $ | 16.8 |
|
| $ | 74.1 |
|
| $ | 70.0 |
|
| $ | 114.8 |
|
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Consolidated net income | $ | 88.1 | $ | 55.3 | $ | 204.6 | $ | 90.1 | ||||||||
Foreign currency translation adjustments | (26.6 | ) | 38.9 | (80.2 | ) | 42.8 | ||||||||||
Derivatives designated as hedging instruments, net of tax | 10.5 | (30.3 | ) | 59.3 | (37.7 | ) | ||||||||||
Pension liability adjustments, net of tax | 1.1 | 0.1 | 4.4 | 14.9 | ||||||||||||
Net comprehensive income | 73.1 | 64.0 | 188.1 | 110.1 | ||||||||||||
Less: Comprehensive income attributable to noncontrolling interests | 0.7 | 1.4 | 0.9 | 1.5 | ||||||||||||
Less: Comprehensive loss attributable to redeemable noncontrolling interest | — | — | — | (0.5 | ) | |||||||||||
Comprehensive income attributable to Bruker Corporation | $ | 72.4 | $ | 62.6 | $ | 187.2 | $ | 109.1 | ||||||||
The following is a summary of the components ofaccumulated other comprehensive income (loss) attributable to Bruker Corporation, net of tax (dollars in(in millions):
|
| Foreign |
|
| Derivatives |
|
| Pension |
|
| Accumulated |
| ||||
Balance at December 31, 2021 |
| $ | 63.1 |
|
| $ | (40.1 | ) |
| $ | (31.2 | ) |
| $ | (8.2 | ) |
Other comprehensive (loss) income before |
|
| (105.8 | ) |
|
| 62.6 |
|
|
| 1.3 |
|
|
| (41.9 | ) |
Realized gain on amounts reclassified from other |
|
| 0 |
|
|
| 0 |
|
|
| 0.8 |
|
|
| 0.8 |
|
Net current period other comprehensive (loss) income |
|
| (105.8 | ) |
|
| 62.6 |
|
|
| 2.1 |
|
|
| (41.1 | ) |
Balance at June 30, 2022 |
| $ | (42.7 | ) |
| $ | 22.5 |
|
| $ | (29.1 | ) |
| $ | (49.3 | ) |
22
Foreign Currency Translation | Derivatives Designated as Hedging Instruments | Pension Liability Adjustment | Accumulated Other Comprehensive Income (Loss) | |||||||||||||
Balance at December 31, 2020 | $ | 140.9 | $ | (91.5 | ) | $ | (45.7 | ) | $ | 3.7 | ||||||
Other comprehensive (loss) income before reclassifications, net of tax | (78.1 | ) | 59.3 | 2.2 | (16.6 | ) | ||||||||||
Realized loss on amounts reclassified from other comprehensive income, net of tax | — | — | 2.2 | 2.2 | ||||||||||||
Net current period other comprehensive (loss) income | (78.1 | ) | 59.3 | 4.4 | (14.4 | ) | ||||||||||
Balance at September 30, 2021 | $ | 62.8 | $ | (32.2 | ) | $ | (41.3 | ) | $ | (10.7 | ) | |||||
Stock-Based Compensation
The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (dollars in(in millions):
|
| Three Months Ended |
|
| Six Months Ended |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
Cost of product revenue |
| $ | 0.3 |
|
| $ | 0.5 |
|
| $ | 0.8 |
|
| $ | 1.0 |
|
Selling, general and administrative |
|
| 3.2 |
|
|
| 2.6 |
|
|
| 5.9 |
|
|
| 5.0 |
|
Research and development |
|
| 0.3 |
|
|
| 0.5 |
|
|
| 0.9 |
|
|
| 1.0 |
|
Total stock-based compensation expense |
| $ | 3.8 |
|
| $ | 3.6 |
|
| $ | 7.6 |
|
| $ | 7.0 |
|
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Costs of product revenue | $ | 0.6 | $ | 0.6 | $ | 1.6 | $ | 1.5 | ||||||||
Selling, general and administrative | 2.6 | 2.9 | 7.6 | 6.9 | ||||||||||||
Research and development | 0.6 | 0.6 | 1.6 | 1.5 | ||||||||||||
Total stock-based compensation | $ | 3.8 | $ | 4.1 | $ | 10.8 | $ | 9.9 | ||||||||
In addition to the awards above, the Company recorded stock-based compensation expense within other charges, net of $0.3$5.9 million and $0.4 million in the three months ended SeptemberJune 30, 2022 and 2021, respectively, and 2020, and $1.1$10.1 million and $1.0$0.8 million in the ninesix months ended SeptemberJune 30, 20212022 and 2020,2021, respectively, related to the 2018 acquisition of Mestrelab.
At SeptemberJune 30, 2021,2022, the Company expectsexpected to recognize$3.3$2.4 million associated with outstanding stock option awards granted under the Company’sCompany's stock plans over the weighted average remaining service period of 2.7 2.0 years. The$30.5$22.0 million associated with outstanding restricted stock units granted under theCompany’s Company's 2016 Incentive Compensation 2.6 2.0 years.
| Nine months ended | ||||||||
| September 30, | ||||||||
| 2021 | 2020 | |||||||
Risk-free interest rates | 0.62 | % | 0.23 | % | ||||
Expected life | 4.43 years | 5.14 years | ||||||
Volatility | 34 | % | 34 | % | ||||
Expected dividend yield | 0.20 | % | 0.37 | % | ||||
| Shares Subject to Options | Weighted Average Option Price | Weighted Average Remaining Contractual Term (Yrs) | Aggregate Intrinsic Value (in millions) (b) | |||||||||||||
Outstanding at December 31, 2020 | 1,856,176 | $ | 25.32 | |||||||||||||
Granted | 79,632 | $ | 85.10 | |||||||||||||
Exercised | (515,692 | ) | $ | 20.40 | ||||||||||||
Forfeited/Expired | — | $ | — | |||||||||||||
Outstanding at September 30, 2021 | 1,420,116 | $ | 30.45 | 4.3 | $ | 68.2 | ||||||||||
Exercisable at September 30, 2021 | 1,158,452 | $ | 24.66 | 3.8 | $ | 61.9 | ||||||||||
Exercisable and expected to vest at September 30, 2021 (a) | 1,384,099 | $ | 29.68 | 4.2 | $ | 67.5 | ||||||||||
| Shares Subject to Restriction | Weighted Average Grant Date Value | |||||||
Outstanding at December 31, 2020 | 805,052 | $ | 39.63 | |||||
Granted | 216,692 | $ | 78.01 | |||||
Vested | (329,840 | ) | $ | 37.07 | ||||
Forfeited | (19,043 | ) | $ | 43.52 | ||||
Outstanding at September 30, 2021 | 672,861 | $ | 53.14 | |||||
The components of other charges, net were asfollows (dollars in(in millions):
|
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
Information technology transformation costs |
| $ | 1.5 |
|
| $ | 0.8 |
|
| $ | 2.5 |
|
| $ | 1.5 |
|
Restructuring charges |
|
| 2.5 |
|
|
| 1.4 |
|
|
| 2.8 |
|
|
| 2.7 |
|
Acquisition-related expenses, net |
|
| 8.3 |
|
|
| 2.3 |
|
|
| 13.4 |
|
|
| 3.2 |
|
Other |
|
| 0.2 |
|
|
| (0.1 | ) |
|
| 1.3 |
|
|
| 0 |
|
Other charges, net |
| $ | 12.5 |
|
| $ | 4.4 |
|
| $ | 20.0 |
|
| $ | 7.4 |
|
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Information technology transformation costs | $ | 1.1 | $ | 0.5 | $ | 2.6 | $ | 1.8 | ||||||||
Professional fees incurred in connection with investigation matters | 0.1 | 0.3 | 0.1 | 4.8 | ||||||||||||
Restructuring charges | 0.9 | 1.7 | 3.6 | 4.4 | ||||||||||||
Acquisition-related charges | 0.6 | 0.9 | 3.8 | (1.0 | ) | |||||||||||
Long-lived asset impairments | (0.6 | ) | 0.7 | (0.6 | ) | 1.9 | ||||||||||
Other | — | 0.1 | — | 0.3 | ||||||||||||
Other charges, net | $ | 2.1 | $ | 4.2 | $ | 9.5 | $ | 12.2 | ||||||||
Restructuring Initiatives
Restructuring chargesinclude charges for various programs that were recorded in the accompanying unaudited condensed consolidated statements of income and comprehensive income. The following table sets forth the restructuring charges (dollars in(in millions):
|
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
Cost of revenues |
| $ | 1.3 |
|
| $ | 0.2 |
|
| $ | 1.4 |
|
| $ | 1.3 |
|
Other charges, net |
|
| 2.5 |
|
|
| 1.4 |
|
|
| 2.8 |
|
|
| 2.7 |
|
Total |
| $ | 3.8 |
|
| $ | 1.6 |
|
| $ | 4.2 |
|
| $ | 4.0 |
|
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Cost of revenues | $ | 0.2 | $ | 0.2 | $ | 1.5 | $ | 1.3 | ||||||||
Other charges, net | 0.9 | 1.7 | 3.6 | 4.4 | ||||||||||||
| $ | 1.6 | $ | 1.9 | $ | 5.1 | $ | 5.7 | |||||||||
The following table sets forth the changes in restructuring reserves (dollars in(in millions):
|
| Total |
|
| Severance |
|
| Exit Costs |
|
| Provisions |
| ||||
Balance at December 31, 2021 |
| $ | 6.4 |
|
| $ | 3.5 |
|
| $ | 0.3 |
|
| $ | 2.6 |
|
Restructuring charges |
|
| 4.2 |
|
|
| 3.2 |
|
|
| 1.0 |
|
|
| 0 |
|
Cash payments |
|
| (5.6 | ) |
|
| (4.5 | ) |
|
| (1.1 | ) |
|
| 0 |
|
Other, non-cash adjustments and foreign currency effect |
|
| (1.5 | ) |
|
| (0.1 | ) |
|
| 0 |
|
|
| (1.4 | ) |
Balance at June 30, 2022 |
| $ | 3.5 |
|
| $ | 2.1 |
|
| $ | 0.2 |
|
| $ | 1.2 |
|
23
Total | Severance | Exit Costs | Provisions for Excess Inventory | |||||||||||||
Balance at December 31, 2020 | $ | 9.8 | $ | 7.6 | $ | 0.8 | $ | 1.4 | ||||||||
Restructuring charges | 5.1 | 4.1 | 1.0 | — | ||||||||||||
Cash payments | (9.7 | ) | (9.0 | ) | (0.7 | ) | — | |||||||||
Other, non-cash adjustments and foreign currency effect | (0.8 | ) | — | (0.7 | ) | (0.1 | ) | |||||||||
Balance at September 30, 2021 | $ | 4.4 | $ | 2.7 | $ | 0.4 | $ | 1.3 | ||||||||
In accordance with ASCAccounting Standards Codification ("ASC") Topic 450, Contingencies, the Company accrues anticipated costs of settlement, damages or other costs to the extent specific losses are probable and estimable.
Litigation and Related Contingencies
Lawsuits, claims and proceedings of a nature considered normal to its businesses may be pending from time to time against the Company. Third parties might allege that the Company or its collaborators are infringing their patent rights or that the Company is otherwise violating their intellectual property rights. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management’s best estimate of probable loss. Disclosure is also provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. The Company believes the outcome of pending proceedings, individually and in the aggregate, will not have a material impact on the Company’s consolidated financial statements.
On September 25, 2019, in a complaint filed in the District Court of Düsseldorf, Germany, District Court, Carl Zeiss Microscopy GmbH, a subsidiary of Carl Zeiss AG (Zeiss), sued Luxendo GmbH (Luxendo), a subsidiary of Bruker Corporation, for infringement of a recently registered German utility model patent licensed to Zeiss pertaining to one specific Luxendo product category. Zeiss is seeking injunctive relief, an accounting indemnification for damages resulting from infringement, and other related remedies. The Company is vigorously defending against this claim.
In addition, the Company is subject to regulation by national, state and local government agencies in the United States and other countries in which the Company operates. From time to time, the Company is the subject of governmental investigations often involving regulatory, marketing and other business practices. These governmental investigations may result in the commencement of civil and criminal proceedings, fines, penalties and administrative remedies which could have a material adverse effect on the Company's financial position, results of operations and/or liquidity.
As of SeptemberJune 30, 20212022 and December 31, 2020, 2021, the Company has 0t recorded any material accruals have been recorded for potential contingencies.
24
15. Business Segment Information
The Company has 3 reportable segments, BSI Life Science, BSI NANONano and BEST, as discussed in Note 1 to the unaudited condensed consolidated financial statements.
Revenue and operating income by reportable segment are presented below (dollars in(in millions):
|
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
BSI Life Science |
| $ | 350.1 |
|
| $ | 341.8 |
|
| $ | 711.1 |
|
| $ | 693.6 |
|
BSI Nano |
|
| 182.2 |
|
|
| 175.3 |
|
|
| 360.7 |
|
|
| 329.7 |
|
BEST |
|
| 59.2 |
|
|
| 56.6 |
|
|
| 118.9 |
|
|
| 109.0 |
|
Eliminations (a) |
|
| (3.1 | ) |
|
| (2.9 | ) |
|
| (7.3 | ) |
|
| (6.8 | ) |
Total revenue |
| $ | 588.4 |
|
| $ | 570.8 |
|
| $ | 1,183.4 |
|
| $ | 1,125.5 |
|
Operating income (loss): |
|
|
|
|
|
|
|
|
|
|
|
| ||||
BSI Life Science |
| $ | 70.2 |
|
| $ | 73.6 |
|
| $ | 156.1 |
|
| $ | 162.5 |
|
BSI Nano |
|
| 14.6 |
|
|
| 21.0 |
|
|
| 36.9 |
|
|
| 33.3 |
|
BEST |
|
| 6.6 |
|
|
| 6.8 |
|
|
| 13.2 |
|
|
| 10.9 |
|
Corporate, eliminations and other (b) |
|
| (17.5 | ) |
|
| (15.8 | ) |
|
| (35.8 | ) |
|
| (32.0 | ) |
Total operating income |
| $ | 73.9 |
|
| $ | 85.6 |
|
| $ | 170.4 |
|
| $ | 174.7 |
|
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Revenue: | ||||||||||||||||
BSI Life Science | $ | 380.7 | $ | 323.4 | $ | 1,074.3 | $ | 842.6 | ||||||||
BSI NANO | 174.9 | 147.1 | 504.6 | 392.7 | ||||||||||||
BEST | 57.0 | 43.8 | 166.0 | 134.8 | ||||||||||||
Eliminations (a) | (3.7 | ) | (2.9 | ) | (10.5 | ) | (10.1 | ) | ||||||||
Total revenue | $ | 608.9 | $ | 511.4 | $ | 1,734.4 | $ | 1,360.0 | ||||||||
Operating Income (loss) | ||||||||||||||||
BSI Life Science | $ | 100.9 | $ | 80.6 | $ | 263.4 | $ | 158.7 | ||||||||
BSI NANO | 21.8 | 12.2 | 55.1 | 9.3 | ||||||||||||
BEST | 7.4 | 1.2 | 18.3 | 5.1 | ||||||||||||
Corporate, eliminations and other (b) | (16.9 | ) | (12.8 | ) | (48.9 | ) | (37.6 | ) | ||||||||
Total operating income | $ | 113.2 | $ | 81.2 | $ | 287.9 | $ | 135.5 | ||||||||
Total assets by reportable segment are as follows (dollars in(in millions):
|
| June 30, |
|
| December 31, |
| ||
Assets: |
|
|
|
|
|
| ||
BSI Life Science, BSI Nano & Corporate |
| $ | 3,298.3 |
|
| $ | 3,560.5 |
|
BEST |
|
| 93.1 |
|
|
| 97.9 |
|
Eliminations and other (a) |
|
| (6.6 | ) |
|
| (8.4 | ) |
Total assets |
| $ | 3,384.8 |
|
| $ | 3,650.0 |
|
September 30, 2021 | December 31, 2020 | |||||||
Assets: | ||||||||
BSI Life Science, BSI NANO & Corporate | $ | 3,038.8 | $ | 2,964.5 | ||||
BEST | 95.1 | 88.7 | ||||||
Eliminations and other (a) | (6.2 | ) | (4.2 | ) | ||||
Total assets | $ | 3,127.7 | $ | 3,049.0 | ||||
The Company is unable, without unreasonable effort or expense, to disclose the amount of total assets held by its BSI Life Science and BSI NANONano segments as well as the Corporate function and further, the Company’s chief operating decision maker does not receive any asset information by operating segment.
25
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion of our financial condition and results of operations should be read in conjunction with our interim unaudited condensed consolidated financial statements and the notes to those statements included in Part 1, Item 1 of this Quarterly Report on2020.
Statements contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this Quarterly Report on FormForward lookingForward-looking statements include, but are not limited to, statements regarding the impact ofandthe impact of supply chain including our implementation of certain cost cutting measures and their impact,challenges, expectations regarding the global economy, inflation, the potential for recession and geopolitical tensions, our intentions regarding our intellectual property, the impact of government contracts and government regulation, our working capital requirements and sufficiency of cash, our competition, the seasonality of our business, the sufficiency of our facilities, our employee relations, the impact of legal or intellectual property proceedings, the impact of changes to tax and accounting rules and changes in law, our anticipated tax rate, our expectations regarding cash dividends, share repurchases, interest expense, interest rate swap agreements, expenses and capital expenditures, the impact of foreign currency exchange rates and changes in commodity prices, the impact of our restructuring initiatives, our expectations regarding backlog and revenue and other risk factors discussed herein and from time to time in our other filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form20202021 and subsequent filings. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.
Non-GAAP
Although our consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP), we believe describing revenue and expenses, excluding the effects of foreign currency, acquisitions and divestitures, as well as certain other charges, net, provides meaningful supplemental information regarding our performance. We rely internally on certain measures that are not calculated according to GAAP. These measures are organic revenue, free cash flow,initiative,initiatives, and other
We define free cash flow as net cash provided by operating activities less additions to property, plant, and equipment. We believe free cash flow is a useful measure to evaluate our business as it indicates the amount of cash generated after additions to property, plant, and equipment which is available for, among other things, investments in our business, acquisitions, share repurchases, dividends and repayment of debt. We regularly use these
26
OVERVIEW
We are a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels. Our corporate headquarters are located in Billerica, Massachusetts. We maintain major technical and manufacturing centers in Europe, Asia and North America and we have sales offices located throughout the world. Bruker is organized into three reportable segments: the BSI Life Science segment (comprised of the Bruker BioSpin Group and the Bruker CALID Group), the BSI NANONano segment and the Bruker Energy & Supercon Technologies (BEST) segment.
Revenue for the three months ended SeptemberJune 30, 20212022 increased by $97.5$17.6 million, or 19.1%3.1%, to $608.9$588.4 million, compared to $511.4$570.8 million for the comparable period in 2020.2021. Included in revenue was a decrease of approximately $41.8 million from unfavorable foreign exchange rate movements, offset by an increase of approximately $5.2 million from foreign currency translation and an increase of $1.3$9.3 million from acquisitions. Excluding the unfavorable effects of foreign currency translationexchange rate movements and our recent acquisitions, our organic revenue, a$91.0$50.1 million. Revenue increases were driven by strong demand for our productsdifferentiated high-value scientific instruments and life science solutions as well as a robust recovery compared to the same period in 2020.
Revenue for the ninesix months ended SeptemberJune 30, 20212022 increased by $374.4$57.9 million, or 27.5%,5.1% to $1,734.4$1,183.4 million, compared to $1,360.0$1,125.5 million for the comparable period in 2020.2021. Included in revenue was a decrease of approximately $65.5 million from unfavorable foreign exchange rate movements, offset by an increase of approximately $60.7 million from foreign currency translation and an increase of $6.3$15.1 million from acquisitions. Excluding the unfavorable effects of foreign currency translationexchange rate movements and our recent acquisitions, our organic revenue, a$307.4$108.3 million. Revenue increases were driven by strong demand for our productsdifferentiated high-value scientific instruments and life science solutions as well as a robust recovery compared to the same period in 2020.
Our gross profit margin increased to 50.7% during the three months ended SeptemberJune 30, 2021,2022, as compared to 48.6%49.2% in the same period in 2020,2021, the result of higher revenue and favorable mix, volume leverage.
Our gross profit margin increased to 50.0%51.1% during the ninesix months ended SeptemberJune 30, 2021,2022, as compared to 46.1%49.7% in the same period in 2020,2021, the result of higher revenue and favorable mix, volume leverage and net favorable mix.
Our income tax provision in the three months ended SeptemberJune 30, 2022 and 2021 and 2020 was $20.7$19.9 million and $20.0$21.3 million, respectively, representing effective tax rates of 19.0%28.6% and 26.6%, respectively. The decrease in our effective tax rate was primarily due to the jurisdictional profit mix, partially offset by the impact of favorable discrete items.
Diluted earnings per share for the three months ended SeptemberJune 30, 20212022 was $0.57, an increase$0.33, a decrease of $0.22$0.05 compared to $0.35$0.38 per share in the same period in 2020.2021. Diluted earnings per share for the ninesix months ended SeptemberJune 30, 20212022 was $1.32, an increase$0.74, a decrease of $0.75$0.01 compared to $0.57$0.75 per share in the same period in 2020.2021. The increasedecrease in net income anddiluted earnings per diluted share in both the three months and ninesix months ended SeptemberJune 30, 20212022 was primarily driven by higher revenue, favorable volumelower net income and operating leverage compared tofrom acquisition related hybrid instrument liability adjustments recognized during the same period in 2020.
The following table presents a reconciliation from net cash provided by operating activities, which is the most directly comparable GAAP operating financial measure, to free cash flow as used by management (in millions):
Nine Months Ended September 30, | ||||||||
2021 | 2020 | |||||||
Net cash provided by operating activities | $ | 143.8 | $ | 129.2 | ||||
Less: purchases of property, plant and equipment | (63.6 | ) | (68.4 | ) | ||||
Free cash flow | $ | 80.2 | $ | 60.8 | ||||
|
| Six Months Ended |
| |||||
|
| 2022 |
|
| 2021 |
| ||
Net cash provided by operating activities |
| $ | 33.4 |
|
| $ | 119.9 |
|
Less: purchases of property, plant and equipment |
|
| (36.9 | ) |
|
| (47.3 | ) |
Free cash flow |
| $ | (3.5 | ) |
| $ | 72.6 |
|
27
The following table presents reconciliations from gross profit and gross profit margin, which are the most directly comparable GAAP operating performance measures, to(dollars in(in millions):
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||||||||||||||||||
Gross profit | $ | 308.7 | 50.7 | % | $ | 248.3 | 48.6 | % | $ | 868.0 | 50.0 | % | $ | 626.8 | 46.1 | % | ||||||||||||||||
Non-GAAP adjustments: | ||||||||||||||||||||||||||||||||
Restructuring costs | 0.2 | — | 0.3 | — | 1.6 | 0.1 | % | 1.3 | 0.1 | % | ||||||||||||||||||||||
Acquisition-related costs | 0.1 | — | 0.5 | 0.1 | % | 0.1 | — | 0.5 | — | |||||||||||||||||||||||
Purchased intangible amortization | 5.3 | 0.9 | % | 5.0 | 1.0 | % | 15.0 | 0.9 | % | 15.1 | 1.1 | % | ||||||||||||||||||||
Other costs | 0.6 | 0.1 | % | (0.3 | ) | (0.1 | %) | 0.1 | — | (0.1 | ) | — | ||||||||||||||||||||
Non-GAAP gross profit | $ | 314.9 | 51.7 | % | $ | 253.8 | 49.6 | % | $ | 884.8 | 51.0 | % | $ | 643.6 | 47.3 | % | ||||||||||||||||
|
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| ||||||||||||||||||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||||||||||||||||||
Gross profit |
| $ | 298.2 |
|
|
| 50.7 | % |
| $ | 280.6 |
|
|
| 49.2 | % |
| $ | 604.5 |
|
|
| 51.1 | % |
| $ | 559.3 |
|
|
| 49.7 | % |
Non-GAAP adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
Restructuring costs |
|
| 1.3 |
|
|
| 0.2 | % |
|
| 0.3 |
|
|
| — |
|
|
| 1.4 |
|
|
| 0.1 | % |
|
| 1.4 |
|
|
| 0.1 | % |
Acquisition-related costs |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 0.2 |
|
|
| — |
|
|
| — |
|
|
| — |
|
Purchased intangible amortization |
|
| 4.5 |
|
|
| 0.8 | % |
|
| 5.2 |
|
|
| 0.9 | % |
|
| 9.0 |
|
|
| 0.8 | % |
|
| 9.7 |
|
|
| 0.8 | % |
Other costs |
|
| 0.7 |
|
|
| 0.1 | % |
|
| (0.5 | ) |
|
| -0.1 | % |
|
| 2.9 |
|
|
| 0.2 | % |
|
| (0.5 | ) |
|
| — |
|
Non-GAAP gross profit |
| $ | 304.7 |
|
|
| 51.8 | % |
| $ | 285.6 |
|
|
| 50.0 | % |
| $ | 618.0 |
|
|
| 52.2 | % |
| $ | 569.9 |
|
|
| 50.6 | % |
Our51.7%51.8% and 49.6%50.0% in the three months ended SeptemberJune 30, 20212022 and 2020,2021, respectively. Our51.0%52.2% and 47.3%50.6% in the ninesix months ended SeptemberJune 30, 20212022 and 2020,2021, respectively. The increases in ourninesix months ended SeptemberJune 30, 20212022 were driven by higher revenue and favorable mix, volume leverage and net favorable impact of foreign exchange rate movements, partially offset by supply chain and logistics challenges compared to 2020 which was negatively impacted by theCOVID-19pandemic. Contributions from higher margin products also favorably impacted our gross profit margin in the nine months ended September 30, 2021.
The following table presents reconciliations from operating income and operating margin, which are the most directly comparable GAAP operating performance measures, to(dollars in(in millions):
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||||||||||||||||||
Operating income | $ | 113.2 | 18.6 | % | $ | 81.2 | 15.9 | % | $ | 287.9 | 16.6 | % | $ | 135.5 | 9.9 | % | ||||||||||||||||
Non-GAAP adjustments: | ||||||||||||||||||||||||||||||||
Restructuring costs | 1.1 | 0.2 | % | 1.9 | 0.4 | % | 5.2 | 0.3 | % | 5.7 | 0.4 | % | ||||||||||||||||||||
Acquisition-related costs | 0.7 | 0.1 | % | 1.4 | 0.3 | % | 3.9 | 0.2 | % | (0.5 | ) | — | ||||||||||||||||||||
Purchased intangible amortization | 9.2 | 1.5 | % | 9.1 | 1.8 | % | 27.2 | 1.6 | % | 26.8 | 2.0 | % | ||||||||||||||||||||
Other costs | 1.2 | 0.2 | % | 1.3 | 0.2 | % | 2.2 | 0.1 | % | 8.6 | 0.6 | % | ||||||||||||||||||||
Non-GAAP operating income | $ | 125.4 | 20.6 | % | $ | 94.9 | 18.6 | % | $ | 326.4 | 18.8 | % | $ | 176.1 | 12.9 | % | ||||||||||||||||
|
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| ||||||||||||||||||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||||||||||||||||||
Operating income |
| $ | 73.9 |
|
|
| 12.6 | % |
| $ | 85.6 |
|
|
| 15.0 | % |
| $ | 170.4 |
|
|
| 14.4 | % |
| $ | 174.7 |
|
|
| 15.5 | % |
Non-GAAP adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
Restructuring costs |
|
| 3.8 |
|
|
| 0.6 | % |
|
| 1.7 |
|
|
| 0.3 | % |
|
| 4.2 |
|
|
| 0.4 | % |
|
| 4.1 |
|
|
| 0.4 | % |
Acquisition-related costs |
|
| 8.3 |
|
|
| 1.4 | % |
|
| 2.3 |
|
|
| 0.4 | % |
|
| 13.6 |
|
|
| 1.1 | % |
|
| 3.2 |
|
|
| 0.3 | % |
Purchased intangible amortization |
|
| 9.3 |
|
|
| 1.6 | % |
|
| 9.0 |
|
|
| 1.6 | % |
|
| 18.6 |
|
|
| 1.6 | % |
|
| 18.0 |
|
|
| 1.6 | % |
Other costs |
|
| 2.4 |
|
|
| 0.4 | % |
|
| 0.2 |
|
|
| — |
|
|
| 6.7 |
|
|
| 0.5 | % |
|
| 1.0 |
|
|
| 0.1 | % |
Non-GAAP operating income |
| $ | 97.7 |
|
|
| 16.6 | % |
| $ | 98.8 |
|
|
| 17.3 | % |
| $ | 213.5 |
|
|
| 18.0 | % |
| $ | 201.0 |
|
|
| 17.9 | % |
Our20.6%16.6% and 18.6%17.3% in the three months ended SeptemberJune 30, 20212022 and 2020,2021, respectively. Our18.8%18.0% and 12.9%17.9% in the ninesix months ended SeptemberJune 30, 20212022 and 2020,2021, respectively. Ourincreaseddecreased in 20212022 due to higher revenue, volumeincreased investments in sales and operating leveragemarketing and in 2021,our research and development capabilities, as compared to 2020.
We can experience
28
Several of these factors have in the past affected and continue to affect the amount and timing of revenue recognized on sales of our products and receipt of related payments and will likely continue to do so in the future. Accordingly, our operating results in any particular quarter may not necessarily be an indication of any future quarter’s operating performance. TheDuringThroughout thefourthree key priorities: the health and safety of our employees, customers and partners; maintaining business continuity and service levels for our customers; executing prudent temporary cost reductions during periods of reduced demand in 2020; and delivering enabling research and diagnostic products to help fight the pandemic, and to support other essential priorities of our society.
Health and safety of our valued employees, customers and partners
In response to the COVID-19 pandemic, we implemented strict social distancing, enhanced cleaning protocols and other preventative measures, such as company-issued face coverings and mandatory mask protocols for unvaccinated employees, in our major facilities.facilities to ensure the health and safety of our valued employees, customers and partners. While many of our office colleagues are workingworked remotely at the height of the pandemic and through subsequent surges, we are placingplaced enhanced focus on the safety of our service organization and factory employees for whom work from home iswas not feasible. Where customer sites arewere accessible and open, our field service organizations operateoperated under social distancing protocols with proper face coverings to ensure the safety of customer sites, when our employees needneeded to be on site. ManyConsistent with local government and health organization guidelines, many of our facilities have begunstarted a gradual return to planthe office for employees who have been working remotely during the pandemicremotely. As we continue to gradually return to the office. Employeemonitor developments and make appropriate adjustments, as needed, employee and visitor health and safety will remain our paramount concern.
Maintaining business continuity and service levels to our customers
Ensuring our ability to supply our enabling technologies and solutions and maintaining high service levels for our customers is another top priority for Bruker. In late March and during parts of April 2020, several of our manufacturing sites underwent temporary controlled shutdowns or were operating at reduced capacity to implement new safety protocols, comply with local rules, and manage cost and inventory levels. These sites thereafter ramped back up with expanding capacity and productivity levels. However, with any resurgence of the virus or the emergence of additional strains of the virus,variants and subvariants, particularly any new strains of the virusthose that are more resistant to existing vaccines, we may again need to consider temporary controlled shutdowns or reduced capacity measures. In addition, we are continuing capital investments in production facilities for efficiencies and expansion. We continue to manageencounter supply chain risks more recently associated with the economic recovery frompandemic, the pandemic, likeglobal economy, including inflation and the threat of recession and geopolitical tensions, and the worldwide shortage of semiconductor chips, components and raw materials, such as copper.
Delivering enabling research and diagnostic products to help fight the pandemic and to support other essential priorities of our society
Bruker is providing critical technologies and solutions to help combat thecrisis, pandemic, most notably our Microbiology and infectious disease diagnostics portfolio and our nuclear magnetic resonance and mass spectrometry systems which are used in critical disease, therapeutic and vaccine research.
Thestrains of the virus,variants and subvariants, or the availability and effectiveness of For additional information on the various risks posed by theCOVID-19pandemic, refer to Item 1A. Risk Factors included in this report.
29
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
This discussion and analysis of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates and judgments, including those related to: revenue recognition; stock-based compensation expense; restructuring and other related charges; income taxes, including the recoverability of deferred tax assets; allowances for doubtful accounts; inventory reductions for excess and obsolete inventories; estimated fair values of long-lived assets used to measure the recoverability of long-lived assets; intangible assets and goodwill; expected future cash flows used to measure the recoverability of intangible assets and long-lived assets; warranty costs; derivative financial instruments; and contingent liabilities. We base our estimates and judgments on our historical experience, current market and economic conditions, industry trends, and other assumptions that we believe are reasonable and form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.
We believe the following critical accounting policies and estimates to be both those most important to the portrayal of our financial position and results of operations and those that require the most estimation and subjective judgment:
For a further discussion of our critical accounting policies, please refer to our Annual Report on Form2020.
30
RESULTS OF OPERATIONS
Three Months Ended SeptemberJune 30, 20212022 compared to the Three Months Ended SeptemberJune 30, 2020
Consolidated Results
The following table presents our results (dollars in millions, except per share data)(in millions):
Three Months Ended September 30, | ||||||||||||||||
2021 | 2020 | Dollar Change | Percentage Change | |||||||||||||
Product revenue | $ | 508.3 | $ | 419.6 | $ | 88.7 | 21.1 | % | ||||||||
Service revenue | 99.0 | 90.0 | 9.0 | 10.0 | % | |||||||||||
Other revenue | 1.6 | 1.8 | (0.2 | ) | (11.1 | )% | ||||||||||
Total revenue | 608.9 | 511.4 | 97.5 | 19.1 | % | |||||||||||
Cost of product revenue | 243.5 | 210.3 | 33.2 | 15.8 | % | |||||||||||
Cost of service revenue | 56.5 | 52.6 | 3.9 | 7.4 | % | |||||||||||
Cost of other revenue | 0.2 | 0.2 | — | — | ||||||||||||
Total cost of revenue | 300.2 | 263.1 | 37.1 | 14.1 | % | |||||||||||
Gross profit | 308.7 | 248.3 | 60.4 | 24.3 | % | |||||||||||
Operating expenses: | ||||||||||||||||
Selling, general and administrative | 141.3 | 114.6 | 26.7 | 23.3 | % | |||||||||||
Research and development | 52.1 | 48.3 | 3.8 | 7.9 | % | |||||||||||
Other charges, net | 2.1 | 4.2 | (2.1 | ) | (50.0 | )% | ||||||||||
Total operating expenses | 195.5 | 167.1 | 28.4 | 17.0 | % | |||||||||||
Operating income | 113.2 | 81.2 | 32.0 | 39.4 | % | |||||||||||
Interest and other income (expense), net | (4.4 | ) | (5.9 | ) | 1.5 | (25.4 | )% | |||||||||
Income before income taxes and noncontrolling interest in consolidated subsidiaries | 108.8 | 75.3 | 33.5 | 44.5 | % | |||||||||||
Income tax provision | 20.7 | 20.0 | 0.7 | 3.5 | % | |||||||||||
Consolidated net income | 88.1 | 55.3 | 32.8 | 59.3 | % | |||||||||||
Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries | 1.0 | 1.0 | — | �� | — | |||||||||||
Net income attributable to Bruker Corporation | $ | 87.1 | $ | 54.3 | $ | 32.8 | 60.4 | % | ||||||||
|
| Three Months Ended |
|
|
|
|
|
|
| |||||||
|
| 2022 |
|
| 2021 |
|
| Dollar |
|
| Percentage |
| ||||
Product revenue |
| $ | 485.8 |
|
| $ | 474.3 |
|
| $ | 11.5 |
|
|
| 2.4 | % |
Service revenue |
|
| 100.9 |
|
|
| 94.7 |
|
|
| 6.2 |
|
|
| 6.5 | % |
Other revenue |
|
| 1.7 |
|
|
| 1.8 |
|
|
| (0.1 | ) |
|
| (5.6 | )% |
Total revenue |
|
| 588.4 |
|
|
| 570.8 |
|
|
| 17.6 |
|
|
| 3.1 | % |
Cost of product revenue |
|
| 230.1 |
|
|
| 236.0 |
|
|
| (5.9 | ) |
|
| (2.5 | )% |
Cost of service revenue |
|
| 60.1 |
|
|
| 54.1 |
|
|
| 6.0 |
|
|
| 11.1 | % |
Cost of other revenue |
|
| — |
|
|
| 0.1 |
|
|
| (0.1 | ) |
|
| (100.0 | )% |
Total cost of revenue |
|
| 290.2 |
|
|
| 290.2 |
|
|
| — |
|
|
| — |
|
Gross profit |
|
| 298.2 |
|
|
| 280.6 |
|
|
| 17.6 |
|
|
| 6.3 | % |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Selling, general and administrative |
|
| 152.2 |
|
|
| 134.8 |
|
|
| 17.4 |
|
|
| 12.9 | % |
Research and development |
|
| 59.6 |
|
|
| 55.8 |
|
|
| 3.8 |
|
|
| 6.8 | % |
Other charges, net |
|
| 12.5 |
|
|
| 4.4 |
|
|
| 8.1 |
|
|
| 184.1 | % |
Total operating expenses |
|
| 224.3 |
|
|
| 195.0 |
|
|
| 29.3 |
|
|
| 15.0 | % |
Operating income |
|
| 73.9 |
|
|
| 85.6 |
|
|
| (11.7 | ) |
|
| (13.7 | )% |
Interest and other income (expense), net |
|
| (4.3 | ) |
|
| (5.6 | ) |
|
| 1.3 |
|
|
| (23.2 | )% |
Income before income taxes and noncontrolling interests in |
|
| 69.6 |
|
|
| 80.0 |
|
|
| (10.4 | ) |
|
| (13.0 | )% |
Income tax provision |
|
| 19.9 |
|
|
| 21.3 |
|
|
| (1.4 | ) |
|
| (6.6 | )% |
Consolidated net income |
|
| 49.7 |
|
|
| 58.7 |
|
|
| (9.0 | ) |
|
| (15.3 | )% |
Net income attributable to noncontrolling interests in |
|
| 0.2 |
|
|
| 1.1 |
|
|
| (0.9 | ) |
|
| (81.8 | )% |
Net income attributable to Bruker Corporation |
| $ | 49.5 |
|
| $ | 57.6 |
|
| $ | (8.1 | ) |
|
| (14.1 | )% |
Revenue
Revenue increases were driven by strong demand for our productsdifferentiated instruments and solutions as well as a robust recovery asoffset by the negative impact of foreign currency translation. The BioSpin Group revenue for the three months ended June 30, 2022 was $159.8 million, an increase of 7.6% compared to the same period in 2020.
Geographically in the second quarter 2022, our North American revenue grew 10.4%, Asia Pacific increased by 14.9%, while European revenue declined by 8.3% compared to the same period in 2021.
Gross Profit
The increase in gross profit in the three months ended SeptemberJune 30, 2021,2022, as compared to the same period in 2020,2021, was a result of higher revenue and favorable mix, volume leverage.
31
Selling, General and Administrative
Our selling, general and administrative expenses for the three months ended SeptemberJune 30, 20212022 increased to 23.2%25.9% of total revenue, from 22.4%23.6% of total revenue for the comparable period in 2020.2021. The increase as a percentage of revenue was a result of the temporary cost reduction measures implemented in the prior period in an effort to mitigate the negative impacts on our business ofCOVID-19the related slowdown in the global economy.
Research and Development
Our research and development expenses for the three months ended SeptemberJune 30, 2021 decreased2022 increased to 8.6%10.1% of total revenue from 9.4%9.8% of total revenue for the comparable period in 2020.2021. The decreaseincrease as a percentage of revenue wasis a result of the increaseour increased investment in revenueresearch and development capabilities period over period in addition to the impact of supply chain constraints on total revenues in the period.
Other Charges, Net
Other charges, net recorded for the three months ended SeptemberJune 30, 20212022 consisted of $1.1$8.3 million of acquisition-related charges related to acquisitions completed in 2022 and 2021, $2.5 million of restructuring costs, $1.5 million of costs associated with our global information technology (IT) transformation activities, $0.9and $0.2 million of restructuring costsother charges. The IT transformation initiative is a multi-year project aimed at updating and $0.6 million of acquisition-related charges related to acquisitions completed in 2021integrating our global enterprise resource planning and 2020.
Other charges, net for the three months ended SeptemberJune 30, 2021 consisted of $2.3 million of acquisition-related charges to acquisitions completed in 2021 and 2020, consisted primarily of $1.7$1.4 million of restructuring costs, related to closing of facilities and implementing outsourcing and other restructuring initiatives, $0.9 million of acquisition-related charges, $0.7 million related to long-lived asset impairments, $0.5$0.8 million of costs associated with our global IT transformation activities and $0.3offset by a $0.1 million adjustment of professional fees incurred in connection with investigation matters.
Operating Income
The increasedecrease in operating income was due to higher revenue, gross profit resulting from differentiated instruments and favorable operating leveragesolutions offset by certain sales and marketing investments and investments research and development capabilities.
Interest and Other Income (Expense), Net
The decline in interest and other income (expense), net in the three months ended SeptemberJune 30, 2021 as our business and end markets rebounded,2022, as compared to the same period in 2020 which2021 was negatively impacted by theCOVID-19pandemic and related economic slowdown.
Income Tax Provision
The 20212022 and 20202021 effective tax rates were estimated using projected annual
The effective tax rates for the three months ended SeptemberJune 30, 2022 and 2021 and 2020 were 19.0%28.6% and 26.6%, respectively. The decreaseincrease in our effective tax rate was primarily due to the jurisdictional profit miximpact of U.S. tax legislation that became effective 2022 limiting the deductibility of research and development expenses and the impactbenefit relating to foreign tax credits and the resolution of favorable discrete items.
Net Income (Loss) Attributable to Noncontrolling Interests
The net income attributable to noncontrolling interests represented the minority shareholders’ proportionate share of the net income recorded by our majority-owned subsidiaries.
32
Reportable Segment Revenue
The following table presents revenue, change in revenue and revenue growth by reportable segment (dollars in(in millions):
|
| Three Months Ended |
|
|
|
|
|
|
| |||||||
|
| 2022 |
|
| 2021 |
|
| Dollar |
|
| Percentage |
| ||||
BSI Life Science |
| $ | 350.1 |
|
| $ | 341.8 |
|
| $ | 8.3 |
|
|
| 2.4 | % |
BSI Nano |
|
| 182.2 |
|
|
| 175.3 |
|
|
| 6.9 |
|
|
| 3.9 | % |
BEST |
|
| 59.2 |
|
|
| 56.6 |
|
|
| 2.6 |
|
|
| 4.6 | % |
Eliminations (a) |
|
| (3.1 | ) |
|
| (2.9 | ) |
|
| (0.2 | ) |
|
|
| |
Total revenue |
| $ | 588.4 |
|
| $ | 570.8 |
|
| $ | 17.6 |
|
|
| 3.1 | % |
Three Months Ended September 30, | Percentage | |||||||||||||||
2021 | 2020 | Dollar Change | Change | |||||||||||||
BSI Life Science | $ | 380.7 | $ | 323.4 | $ | 57.3 | 17.7 | % | ||||||||
BSI NANO | 174.9 | 147.1 | 27.8 | 18.9 | % | |||||||||||
BEST | 57.0 | 43.8 | 13.2 | 30.1 | % | |||||||||||
Eliminations (a) | (3.7 | ) | (2.9 | ) | (0.8 | ) | ||||||||||
| $ | 608.9 | $ | 511.4 | $ | 97.5 | 19.1 | % | |||||||||
For financial reporting purposes, we aggregate the Bruker BioSpin Group and Bruker CALID Group as the BSI Life Science segment. This aggregation reflects the similar economic characteristics, production processes, customer services provided, types and classes of customers, methods of distribution and regulatory environments.
The increase in revenue for the BSI Life Science segment in the three months ended SeptemberJune 30, 20212022 was due to strong demand, business and end market recovery, and was led by growth in infraredrecognition of an ultra-high-field NMR system as well as from services and Raman, Nuclear Magnetic Resonance (NMR), and Preclinical Imaging (PCI) solutions.support offset by supply chain constraints. The increase in revenue for the BSI NANONano segment was driven by a reboundstrong demand in industrial research and academic market demand and continued strong demand from semiconductor and microelectronics customers. The increase in revenue for the BEST segment resulted from higher “big science” project revenue and a recovery in superconductors for healthcare MRI in the three months ended September 30, 2021.
Operating Income
The following table presents operating income and operating margins on revenue by reportable segment (dollars in(in millions):
Three Months Ended September 30, | ||||||||||||||||
2021 | 2020 | |||||||||||||||
Operating Income (Loss) | Percentage of Segment Revenue | Operating Income (Loss) | Percentage of Segment Revenue | |||||||||||||
BSI Life Science | $ | 100.9 | 26.5 | % | $ | 80.6 | 24.9 | % | ||||||||
BSI NANO | 21.8 | 12.5 | % | 12.2 | 8.3 | % | ||||||||||
BEST | 7.4 | 13.0 | % | 1.2 | 2.7 | % | ||||||||||
Corporate, eliminations and other (a) | (16.9 | ) | (12.8 | ) | ||||||||||||
Total operating income | $ | 113.2 | 18.6 | % | $ | 81.2 | 15.9 | % | ||||||||
|
| Three Months Ended June 30, |
| |||||||||||||
|
| 2022 |
|
| 2021 |
| ||||||||||
|
| Operating |
|
| Percentage of |
|
| Operating |
|
| Percentage of |
| ||||
BSI Life Science |
| $ | 70.2 |
|
|
| 20.1 | % |
| $ | 73.6 |
|
|
| 21.5 | % |
BSI Nano |
|
| 14.6 |
|
|
| 8.0 | % |
|
| 21.0 |
|
|
| 12.0 | % |
BEST |
|
| 6.6 |
|
|
| 11.1 | % |
|
| 6.8 |
|
|
| 12.0 | % |
Corporate, eliminations and other (a) |
|
| (17.5 | ) |
|
|
|
|
| (15.8 | ) |
|
|
| ||
Total operating income |
| $ | 73.9 |
|
|
| 12.6 | % |
| $ | 85.6 |
|
|
| 15.0 | % |
(a) Represents corporate costs and eliminations not allocated to the reportable segments.
The operating margin increasesdecreases in the BSI Life Science and BSI NANONano segments resultedwas primarily due to higher gross margin resulting from higher revenue and favorable mix, volume leverage and operating leverage.net favorable impact of foreign exchange rate movements offset by planned sales and marketing investments, supply chain and logistics challenges and inflationary margin challenges in 2022, as compared to 2021, and investments in research and development capabilities. The operating margin increasedecrease in the BEST segment resulted from higher revenue and favorable mix.
33
Consolidated Results
Six Months Ended SeptemberJune 30, 20212022 compared to the NineSix Months Ended SeptemberJune 30, 2020
The following table presents our results (dollars in millions, except per share data)(in millions):
Nine Months Ended September 30, | ||||||||||||||||
2021 | 2020 | Dollar Change | Percentage Change | |||||||||||||
Product revenue | $ | 1,441.2 | $ | 1,111.6 | $ | 329.6 | 29.7 | % | ||||||||
Service revenue | 287.8 | 244.3 | 43.5 | 17.8 | % | |||||||||||
Other revenue | 5.4 | 4.1 | 1.3 | 31.7 | % | |||||||||||
Total revenue | 1,734.4 | 1,360.0 | 374.4 | 27.5 | % | |||||||||||
Cost of product revenue | 700.4 | 584.1 | 116.3 | 19.9 | % | |||||||||||
Cost of service revenue | 165.3 | 148.4 | 16.9 | 11.4 | % | |||||||||||
Cost of other revenue | 0.7 | 0.7 | — | — | ||||||||||||
Total cost of revenue | 866.4 | 733.2 | 133.2 | 18.2 | % | |||||||||||
Gross profit | 868.0 | 626.8 | 241.2 | 38.5 | % | |||||||||||
Operating expenses: | ||||||||||||||||
Selling, general and administrative | 407.9 | 338.2 | 69.7 | 20.6 | % | |||||||||||
Research and development | 162.7 | 140.9 | 21.8 | 15.5 | % | |||||||||||
Other charges, net | 9.5 | 12.2 | (2.7 | ) | (22.1 | )% | ||||||||||
Total operating expenses | 580.1 | 491.3 | 88.8 | 18.1 | % | |||||||||||
Operating income | 287.9 | 135.5 | 152.4 | 112.5 | % | |||||||||||
Interest and other income (expense), net | (13.8 | ) | (15.4 | ) | 1.6 | (10.4 | )% | |||||||||
Income before income taxes and noncontrolling interest in consolidated subsidiaries | 274.1 | 120.1 | 154.0 | 128.2 | % | |||||||||||
Income tax provision | 69.5 | 30.0 | 39.5 | 131.7 | % | |||||||||||
Consolidated net income | 204.6 | 90.1 | 114.5 | 127.1 | % | |||||||||||
Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries | 3.2 | 1.2 | 2.0 | 166.7 | % | |||||||||||
Net income attributable to Bruker Corporation | $ | 201.4 | $ | 88.9 | $ | 112.5 | 126.5 | % | ||||||||
|
| Six Months Ended June 30, |
|
|
|
|
|
|
| |||||||
|
| 2022 |
|
| 2021 |
|
| Dollar |
|
| Percentage |
| ||||
Product revenue |
| $ | 976.2 |
|
| $ | 932.9 |
|
| $ | 43.3 |
|
|
| 4.6 | % |
Service revenue |
|
| 204.1 |
|
|
| 188.8 |
|
|
| 15.3 |
|
|
| 8.1 | % |
Other revenue |
|
| 3.1 |
|
|
| 3.8 |
|
|
| (0.7 | ) |
|
| (18.4 | )% |
Total revenue |
|
| 1,183.4 |
|
|
| 1,125.5 |
|
|
| 57.9 |
|
|
| 5.1 | % |
Cost of product revenue |
|
| 459.1 |
|
|
| 456.9 |
|
|
| 2.2 |
|
|
| 0.5 | % |
Cost of service revenue |
|
| 119.7 |
|
|
| 108.8 |
|
|
| 10.9 |
|
|
| 10.0 | % |
Cost of other revenue |
|
| 0.1 |
|
|
| 0.5 |
|
|
| (0.4 | ) |
|
| (80.0 | )% |
Total cost of revenue |
|
| 578.9 |
|
|
| 566.2 |
|
|
| 12.7 |
|
|
| 2.2 | % |
Gross profit |
|
| 604.5 |
|
|
| 559.3 |
|
|
| 45.2 |
|
|
| 8.1 | % |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Selling, general and administrative |
|
| 297.9 |
|
|
| 266.6 |
|
|
| 31.3 |
|
|
| 11.7 | % |
Research and development |
|
| 116.2 |
|
|
| 110.6 |
|
|
| 5.6 |
|
|
| 5.1 | % |
Other charges, net |
|
| 20.0 |
|
|
| 7.4 |
|
|
| 12.6 |
|
|
| 170.3 | % |
Total operating expenses |
|
| 434.1 |
|
|
| 384.6 |
|
|
| 49.5 |
|
|
| 12.9 | % |
Operating income |
|
| 170.4 |
|
|
| 174.7 |
|
|
| (4.3 | ) |
|
| (2.5 | )% |
Interest and other income (expense), net |
|
| (6.8 | ) |
|
| (9.4 | ) |
|
| 2.6 |
|
|
| (27.7 | )% |
Income before income taxes and noncontrolling interests in |
|
| 163.6 |
|
|
| 165.3 |
|
|
| (1.7 | ) |
|
| (1.0 | )% |
Income tax provision |
|
| 51.8 |
|
|
| 48.8 |
|
|
| 3.0 |
|
|
| 6.1 | % |
Consolidated net income |
|
| 111.8 |
|
|
| 116.5 |
|
|
| (4.7 | ) |
|
| (4.0 | )% |
Net income attributable to noncontrolling interests in |
|
| 0.7 |
|
|
| 2.2 |
|
|
| (1.5 | ) |
|
| (68.2 | )% |
Net income attributable to Bruker Corporation |
| $ | 111.1 |
|
| $ | 114.3 |
|
| $ | (3.2 | ) |
|
| (2.8 | )% |
Revenue
Revenue increases were driven by strong broad demand for our productsdifferentiated instruments and solutions offset by the negative impact of foreign currency translation. The BioSpin Group revenue for the six months ended June 30, 2022 was $317.6 million, an increase of 3.2% compared to the same period in 2021. The increase was driven by strong growth in the applied markets. The CALID Group revenue for the six months ended June 30, 2022 was $393.5 million, a slight increase of 2.0% compared to the same period in 2021. The increase in revenues was a direct result of strong growth in life science mass spectrometry and microbiology aftermarket business, but also impacted by supply chain constraints. BSI Nano revenue for the businesssix months ended June 30, 2022 was $360.7 million, an increase of 9.4% compared to the same period in 2021. The increase in BSI Nano revenue was driven by strong demand in its industrial and end market recoverysemiconductor metrology markets. The BEST revenue for the six months ended June 30, 2022 was $118.9 million, an increase of 9.1% compared to the same period in 2021, driven by strong superconductor demand from major medical magnetic resonance imaging manufacturers.
Geographically in the six months ended June 30, 2022, our North American revenue grew 19.8%, Asia Pacific increased by 9.3%, while European revenue declined by 8.3% compared to the same period in 2021.
Gross Profit
The increase in gross profit in the six months ended June 30, 2022, as compared to the same period in 2020.
34
Selling, General and Administrative
Our selling, general and administrative expenses for the ninesix months ended SeptemberJune 30, 2021 decreased2022 increased to 23.5%25.2% of total revenue, from 24.9%23.7% of total revenue for the comparable period in 2020.2021. The decreaseincrease as a percentage of revenue was a result of the increaseinvestments in revenue period over period.
Research and Development
Our research and development expenses for the nine months ended September 30, 2021 decreased to 9.4% of total revenue from 10.4%as a percentage of total revenue for the comparablesix months ended June 30, 2022 was 9.8% equal to the same period in 2020.2021. The decrease as aconsistent percentage of revenue was a result of the increaserelates to higher overall revenues in revenueaddition to our increased investment in research and development capabilities period over period.
Other Charges, Net
Other charges, net recorded for the ninesix months ended SeptemberJune 30, 20212022 consisted of $3.8$13.4 million of acquisition-related charges related to acquisitions completed in 2022 and 2021, $2.8 million of restructuring costs, $2.5 million of costs associated with our global information technology (IT) transformation activities, $0.8 million of other charges, and $0.5 million related to suspension of operations in Russia.
Other charges, net for the six months ended June 30, 2021 consisted of $3.2 million of acquisition-related charges to acquisitions completed in 2021 and 2020, $3.6$2.7 million of restructuring costs and $2.6$1.5 million of costs associated with our global IT transformation activities.
Operating Income
The increasedecrease in operating income was due to higher revenue, gross profit resulting from higher revenue and favorable operatingmix, volume leverage and net favorable impact of foreign exchange rate movements offset by planned sales and marketing investments, supply chain and logistics challenges and inflationary margin challenges in 2022, as compared to 2021, and investments in research and development capabilities.
Interest and Other Income (Expense), Net
The decline in interest and other income (expense), net in the ninesix months ended SeptemberJune 30, 2021 as our business and end markets rebounded,2022, as compared to the same period in 2020 which2021 was negatively impacted by theCOVID-19pandemic and related economic slowdown.
Income Tax Provision
The 20212022 and 20202021 effective tax rates were estimated using projected annual
The effective tax rates for the ninesix months ended SeptemberJune 30, 2022 and 2021 were 31.7% and 2020 were 25.4% and 25.0%,29.5% respectively. The increase in our effective tax rate was primarily due to the increaseimpact of U.S. tax legislation that became effective in profit before income tax2022 limiting the deductibility of research and development expenses and the jurisdictional profit mix, partially offset bybenefit relating to foreign tax credits and the impactresolution of discrete items in the period.
Net Income (Loss) Attributable to Noncontrolling Interests
The net income attributable to noncontrolling interests represented the minority shareholders’ proportionate share of the net income recorded by our majority-owned subsidiaries.
35
Reportable Segment Revenue
The following table presents revenue, change in revenue and revenue growth by reportable segment (dollars in(in millions):
|
| Six Months Ended June 30, |
|
|
|
|
|
|
| |||||||
|
| 2022 |
|
| 2021 |
|
| Dollar |
|
| Percentage |
| ||||
BSI Life Science |
| $ | 711.1 |
|
| $ | 693.6 |
|
| $ | 17.5 |
|
|
| 2.5 | % |
BSI Nano |
|
| 360.7 |
|
|
| 329.7 |
|
|
| 31.0 |
|
|
| 9.4 | % |
BEST |
|
| 118.9 |
|
|
| 109.0 |
|
|
| 9.9 |
|
|
| 9.1 | % |
Eliminations (a) |
|
| (7.3 | ) |
|
| (6.8 | ) |
|
| (0.5 | ) |
|
|
| |
Total revenue |
| $ | 1,183.4 |
|
| $ | 1,125.5 |
|
| $ | 57.9 |
|
|
| 5.1 | % |
Nine Months Ended September 30, | Percentage Change | |||||||||||||||
2021 | 2020 | Dollar Change | ||||||||||||||
BSI Life Science | $ | 1,074.3 | $ | 842.6 | $ | 231.7 | 27.5 | % | ||||||||
BSI NANO | 504.6 | 392.7 | 111.9 | 28.5 | % | |||||||||||
BEST | 166.0 | 134.8 | 31.2 | 23.1 | % | |||||||||||
Eliminations (a) | (10.5 | ) | (10.1 | ) | (0.4 | ) | ||||||||||
| $ | 1,734.4 | $ | 1,360.0 | $ | 374.4 | 27.5 | % | |||||||||
The increase in revenue for the BSI Life Science segment in the ninesix months ended SeptemberJune 30, 20212022 was due to strong demand, and business and end market recovery, acrossand was led by recognition of an ultra-high-field NMR system as well as strong growth in the segment’s major product lines, including mass spectrometry, infrared, Raman, microbiology, Nuclear Magnetic Resonance (NMR) and Preclinical Imaging (PCI) solutions. In addition, system installation activities recovered compared to the same period in 2020.applied markets offset by supply chain constraints. The increase in revenue for the BSI NANONano segment was driven by a reboundstrong demand in industrial research and academic market demand and continued strong demand from semiconductor and microelectronics customers. The increase in revenue for the BEST segment resulted from higher “big science” project revenue and a recovery in superconductors for healthcare MRI in the three months ended September 30, 2021.
Operating Income
The following table presents operating income and operating margins on revenue by reportable segment (dollars in(in millions):
Nine Months Ended September 30, | ||||||||||||||||
2021 | 2020 | |||||||||||||||
Operating Income (Loss) | Percentage of Segment Revenue | Operating Income (Loss) | Percentage of Segment Revenue | |||||||||||||
BSI Life Science | $ | 263.4 | 24.5 | % | $ | 158.7 | 18.8 | % | ||||||||
BSI NANO | 55.1 | 10.9 | % | 9.3 | 2.4 | % | ||||||||||
BEST | 18.3 | 11.0 | % | 5.1 | 3.8 | % | ||||||||||
Corporate, eliminations and other (a) | (48.9 | ) | (37.6 | ) | ||||||||||||
Total operating income | $ | 287.9 | 16.6 | % | $ | 135.5 | 10.0 | % | ||||||||
|
| Six Months Ended June 30, |
| |||||||||||||
|
| 2022 |
|
| 2021 |
| ||||||||||
|
| Operating |
|
| Percentage of |
|
| Operating |
|
| Percentage of |
| ||||
BSI Life Science |
| $ | 156.1 |
|
|
| 22.0 | % |
| $ | 162.5 |
|
|
| 23.4 | % |
BSI Nano |
|
| 36.9 |
|
|
| 10.2 | % |
|
| 33.3 |
|
|
| 10.1 | % |
BEST |
|
| 13.2 |
|
|
| 11.1 | % |
|
| 10.9 |
|
|
| 10.0 | % |
Corporate, eliminations and other (a) |
|
| (35.8 | ) |
|
|
|
|
| (32.0 | ) |
|
|
| ||
Total operating income |
| $ | 170.4 |
|
|
| 14.4 | % |
| $ | 174.7 |
|
|
| 15.5 | % |
(a) Represents corporate costs and eliminations not allocated to the reportable segments.
The operating margin increases in the BSI Life Science and BSI NANONano segments resultedwas primarily due to higher gross margin resulting from higher revenue, volumedifferentiated products and operating leverage.leverage, partially offset by planned commercial investments. The operating margin increase in the BEST segment resulted from higher revenue and favorable mix.
LIQUIDITY AND CAPITAL RESOURCES
We anticipate that our existing cash and credit facilities will be sufficient to support our operating and investing needs for at least the next twelve months. Our future cash requirements could be affected by acquisitions that we may complete, purchases of our common stock or the payment of dividends in the future. Historically, we have financed our growth and liquidity needs through cash flow generation from operations and a combination of debt financings and issuances of common stock. In the future, there are no assurances that we will continue to generate cash flow from operations or that additional financing alternatives will be available to us, if required, or if available, will be obtained on terms favorable to us.
Cash, cash equivalents and short-term investments at SeptemberJune 30, 20212022 and December 31, 20202021 totaled $669.8$723.0 million and $731.8$1,168.2 million, respectively, of which $560.1$561.3 million and $514.9$646.9 million, respectively, related to cash, cash equivalents and short-term investments held outside of the U.S. in our foreign subsidiaries, most significantly in the Netherlands, Switzerland and Hong Kong.
36
The following table presents our cash flows from operating activities, investing activities and financing activities for the periods presented (in millions):
Nine Months Ended September 30, | ||||||||
2021 | 2020 | |||||||
Net cash provided by operating activities | $ | 143.8 | $ | 129.2 | ||||
Net cash used in investing activities | (143.8 | ) | (163.9 | ) | ||||
Net cash used in financing activities | (85.6 | ) | (87.3 | ) | ||||
Effect of exchange rates on cash and cash equivalents | (23.4 | ) | 10.7 | |||||
Total decrease in cash and cash equivalents | $ | (109.0 | ) | $ | (111.3 | ) | ||
|
| Six Months Ended June 30, |
| |||||
|
| 2022 |
|
| 2021 |
| ||
Net cash provided by operating activities |
| $ | 33.4 |
|
| $ | 119.9 |
|
Net cash used in investing activities |
|
| (44.7 | ) |
|
| (95.4 | ) |
Net cash used in financing activities |
|
| (297.2 | ) |
|
| (83.0 | ) |
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
|
| (36.9 | ) |
|
| (15.3 | ) |
Net change in cash, cash equivalents and restricted cash |
| $ | (345.4 | ) |
| $ | (73.8 | ) |
Cash provided by operating activities during the ninesix months ended SeptemberJune 30, 20212022 resulted primarily from consolidated net income adjusted for$300.9$168.5 million, partially offset by a change in operating assets and liabilities, net of acquisitions and divestitures of $157.1$135.1 million. The decrease was primarily due to strategic inventory management to handle supply chain challenges, timing of tax payments partially offset by customer advances received during the period related to new orders and deferral of revenue due to supply chain challenges. Cash provided by operating activities during the six months ended June 30, 2021 resulted from consolidated net income adjusted for non-cash items of $185.1 million, partially offset by a change in operating assets and liabilities, net of acquisitions and divestitures of $65.2 million. The primary increase is a result of increased net income driven by the increase in revenue, gross profit and operating profit as a result of the rebounding in our business and end markets. The decrease in operating assets and liabilities, net of acquisitions and divestitures for the ninesix months ended SeptemberJune 30, 2021 was primarily due to strategicimproved inventory management, to handle supply chain challenges, timing of tax paymenthigher payables and increased revenues at the end of the period. These decreases wereaccrued liabilities partially offset by a decrease in cash received from customers due to timing of payments as compared to the same period in the prior year. During the nine months ended September 30, 2020, net cash provided by operating activities was $129.2 million, resulting from consolidated net income adjusted fornon-cashitems of $185.7 million, offset by a change in operating assets and liabilities, net of acquisitions and divestitures of $56.5 million. The increase in operating assets and liabilities, net of acquisitions and divestitures for the nine months ended September 30, 2020 was primarily caused by an increase in cash received from customers offset by purchases of inventory for orders in 2020.
Cash used in investing activities during the ninesix months ended SeptemberJune 30, 2022 resulted primarily from acquisitions of $85.4 million, purchases of property, plant and equipment of $36.9 million, and strategic investments of $38.1 million, offset by maturity of short-term investments of $100.0 million and $13.8 million of net proceeds from sales of property, plant and equipment. Cash used in investing activities during the six months ended June 30, 2021 resulted primarilymainly from purchases of property, plant and equipment of $63.6$47.3 million, purchases of short-term investments of $48.0 million and acquisitions of $45.0 million offset by $8.6 million of net proceeds from our cross-currency swap agreements. Cash used in investing activities during the nine months ended September 30, 2020 was primarily attributed to cash paid for purchases of property, plant and equipment of $68.4 million, cash paid for acquisitions of $58.8 million and purchases of short-term investments of $100.0 million offset by $7.1 million of net proceeds from our cross-currency swap agreements and $56.1 million of maturities in short-term investments.
Net cash used in financing activities during the ninesix months ended SeptemberJune 30, 2022 was primarily from cash paid for purchases of common stock under our repurchase program of $165.9 million, repayment of our 2012 Note Purchase Agreement of $105.0 million and $15.0 million for the payment of dividends. Net cash used in financing activities during the six months ended June 30, 2021 was primarily from cash paid for purchases of common stock under our repurchase program of $71.1 million and $18.2$12.1 million for the payment of dividends. Net cash used in financing activities during the nine months ended September 30, 2020 was primarily attributable to $54.4 million of repurchases of common stock under our repurchase program, $18.5 million for the payment of dividends, $7.6 million in net payments of borrowings under the 2019 Revolving Credit Agreement and $6.2 million payment of contingent consideration.
Share Repurchase Program
In May 2019, our Board of Directors approved our share repurchase program (the “2019 Repurchase Program”) under which repurchases of common stock in the amount of up to $300.0 million were authorized to occur from time to time, in amounts, at prices, and at such times as we deem appropriate, subject to market conditions, legal requirements and other considerations. During the ninethree months ended SeptemberJune 30, 2021, we repurchasedpurchased 24,873 shares at an aggregate cost of $1.7 million under the 2019 Repurchase Program. During the six months ended June 30, 2021, we purchased a total of 555,602 shares at an aggregate cost of $34.5 million under the 2019 Repurchase Program. We completed the 2019 Repurchase Program in April 2021, after reaching the maximum cumulative spend.
In May 2021, our Board of Directors approved a share repurchase program (the “2021 Repurchase Program”) authorizing the purchase of up to $500.0 million of our common stock over aninethree months ended SeptemberJune 30, 2021,2022, we purchased 530,703983,741 shares of common stock withat an aggregate cost of approximately $36.6$60.3 million under the 2021 Repurchase Program. NoDuring the six months ended June 30, 2022, we purchased a total of 2,586,796 shares wereat an aggregate cost of $165.9 million under the 2021 Repurchase Program. We purchased duringa total of 530,703 shares with an aggregate cost of $36.6 million in the three and six months ended September 30, 2021. At SeptemberJune 30, 2021 $463.4under the 2021 Repurchase Program. At June 30, 2022, $215.3 million remained for future purchase under the 2021 Repurchase Program. We intend to fund any additional repurchases from cash on hand, future cash flows from operations and available borrowings under our revolving credit facility. The purchased shares are reflected within Treasury stock in the accompanying unaudited condensed consolidated balance sheets.
37
On December 11, 2019, we entered into (1) a new revolving credit agreement to establish a new revolving credit facility in the aggregate principal amount of $600 million; (2) a term loan agreement to establish a new term loan facility in the aggregate principal amount of $300 million; and (3) a note purchase agreement to issue and sell CHF 297 million aggregate principal amount of 1.01% senior notes due December 11, 2029. Floating interest rates under the term loan were simultaneously fixed through cross-currency and interest rate swap agreements into Euro ($150 million) and Swiss Franc ($150 million) rates carrying average effective interest rates of 0.94% and hedge our net investment in our Euro and Swiss Franc denominated net assets. The new revolving credit agreement replaced our $500 million five-year revolving credit agreement established on October 27, 2015, that was terminated on December 11, 2019.
In addition, we designated our CHF 297 million senior notes as a hedge in our net investment in our Swiss Franc denominated net assets. Proceeds from this financing were used to repay the outstanding borrowings under our prior 2015 revolving credit facility and we intend to use the remaining proceeds for general corporate purposes and to support corporate strategic objectives. During December 2019, we entered into U.S. Dollar to Euro cross-currency swaps on our existing 2012 private placement notes of $105 million of 4.31% Series 2012A Senior Notes, Tranche C, duerepaid in January 18, 2022, and the existing $100 million of 4.46% Series 2012A Senior Notes, Tranche D, due January 18, 2024, resulting in an average effective interest rate of 2.25% on these instruments. The cross-currency swaps hedge our net investment in our Euro denominated net assets.
As of June 30, 2022, we have several cross-currency and interest rate swap agreements with a notional value of $148.9 million of U.S. to Swiss Franc and a notional value of $248.9 million of U.S. to Euro to hedge the variability in the movement of foreign currency exchange rates on portions of our Euro and Swiss Franc denominated net asset investments. As a result of entering into these interest rate and cross currency swap agreements, we reduced ourthe Company lowered net interest expense by $1.4$1.6 million for each ofand $1.3 million during the three months ended SeptemberJune 30, 2022 and 2021, respectively and 2020, and by $4.1$2.7 million and $5.8 million forduring each of the ninesix months ended SeptemberJune 30, 20212022 and 2020,2021, respectively. We anticipate these swap agreements will lower net interest expense in future years.
We had the following debt outstanding (dollars in(in millions):
September 30, 2021 | December 31, 2020 | |||||||
US Dollar notes under the 2012 Note Purchase Agreement | $ | 205.0 | $ | 205.0 | ||||
CHF notes (in dollars) under the 2019 Note Purchase Agreement | 318.1 | 335.5 | ||||||
US Dollar notes under the 2019 Term Loan | 300.0 | 300.0 | ||||||
Unamortized debt issuance costs | (2.1 | ) | (2.4 | ) | ||||
Finance lease obligations and other loans | 6.0 | 6.4 | ||||||
Total debt | 827.0 | 844.5 | ||||||
Current portion of long-term debt | (109.5 | ) | (2.2 | ) | ||||
Total long-term debt, less current portion | $ | 717.5 | $ | 842.3 | ||||
|
| June 30, |
|
| December 31, |
| ||
EUR notes (in U.S. dollars) under the 2021 Note Purchase Agreement |
| $ | 157.3 |
|
| $ | 170.7 |
|
CHF notes (in U.S. dollars) under the 2021 Note Purchase Agreement |
|
| 314.5 |
|
|
| 329.2 |
|
CHF notes (in U.S. dollars) under the 2019 Note Purchase Agreement |
|
| 311.4 |
|
|
| 325.9 |
|
U.S. Dollar notes under the 2019 Term Loan |
|
| 297.8 |
|
|
| 299.2 |
|
U.S. Dollar notes under the 2012 Note Purchase Agreement |
|
| 100.0 |
|
|
| 205.0 |
|
Unamortized debt issuance costs |
|
| (1.8 | ) |
|
| (2.0 | ) |
Other loans |
|
| 1.8 |
|
|
| 1.9 |
|
Total notes and loans outstanding |
|
| 1,181.0 |
|
|
| 1,329.9 |
|
Finance lease obligations |
|
| 4.0 |
|
|
| 4.3 |
|
Total debt |
|
| 1,185.0 |
|
|
| 1,334.2 |
|
Current portion of long-term debt |
|
| (14.0 | ) |
|
| (112.4 | ) |
Total long-term debt, less current portion |
| $ | 1,171.0 |
|
| $ | 1,221.8 |
|
As of SeptemberJune 30, 2021, there are no material changes to our contractual obligations from those disclosed in our Annual Report on Form10-Kfor the fiscal year ended December 31, 2020.
The following is a summary of the maximum commitments and the net amounts available to us under the 2019 Credit Agreement and other lines of credit with various financial institutions located primarily in Germany and Switzerland that are unsecured and typically due upon demand with interest payable monthly, at SeptemberJune 30, 2021 (dollars in2022 (in millions):
Weighted Average Interest Rate | Total Amount Committed by Lenders | Outstanding Borrowings | Outstanding Letters of Credit | Total Committed Amounts Available | ||||||||||||||||
2019 Credit Agreement | 1.3 | % | $ | 600.0 | $ | — | $ | 0.1 | $ | 599.9 | ||||||||||
Bank guarantees and working capital line | varies | 115.2 | — | 115.2 | — | |||||||||||||||
Total revolving lines of credit | $ | 715.2 | $ | — | $ | 115.3 | $ | 599.9 | ||||||||||||
|
| Weighted |
|
| Total Amount |
|
| Outstanding |
|
| Outstanding |
|
| Total |
| |||||
2019 Credit Agreement |
|
| 1.3 | % |
| $ | 600.0 |
|
| $ | — |
|
| $ | 0.1 |
|
| $ | 599.9 |
|
Bank guarantees and working capital line |
| varies |
|
|
| 108.7 |
|
|
| — |
|
|
| 108.7 |
|
|
| — |
| |
Total revolving lines of credit |
|
|
|
| $ | 708.7 |
|
| $ | — |
|
| $ | 108.8 |
|
| $ | 599.9 |
| |
38
As of SeptemberJune 30, 2021,2022, wein compliancecompliant with the financial covenants of these debt agreements.
RECENT ACCOUNTING PRONOUNCEMENTS
Information regarding recent accounting standard changes and developments is incorporated by reference from Part I, Item 1, Unaudited Condensed Consolidated Financial Statements, of this document and should be considered an integral part of this Item 2. See Note 2 in the Notes to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form
39
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are potentially exposed to market risks associated with changes in foreign currency translation rates, interest rates and commodity prices. We selectively use financial instruments to reduce these risks. All transactions related to risk management techniques are authorized and executed pursuant to our policies and procedures. Analytical techniques used to manage and monitor foreign currency translation and interest rate risk include market valuations and sensitivity analysis.
Foreign Currency Risk
We generate a substantial portion of our revenues in international markets, principally Germany and other countries in the European Union, Switzerland and Japan, which exposes our operations to the risk of exchange rate fluctuations. The impact of currency exchange rate movement can be positive or negative in any period. Our costs related to sales in foreign currencies are largely denominated in the same respective currencies, reducing our transaction risk exposure. However, for foreign currency denominated sales in certain regions, such as Japan, where we do not incur significant costs denominated in Japanese Yen, we are more exposed to the impact of foreign currency fluctuations.
For sales not denominated in U.S. dollars, if there is an increase in the rate at which a foreign currency is exchanged for U.S. dollars, it will require more of the foreign currency to equal a specified amount of U.S. dollars than before the rate increase. In such cases, if we price our products in the foreign currency, we will receive less in U.S. dollars than we would have received before the rate increase went into effect. If we price our products in U.S. dollars and competitors price their products in local currency, an increase in the relative strength of the U.S. dollar could result in our prices not being competitive in a market where business is transacted in the local currency. For example, if the U.S. dollar strengthened against the Japanese Yen, our Japanese-based competitors would have a greater pricing advantage over us.
Changes in foreign currency translation rates decreased our revenue by 7.3% and increased our revenue by 1.0% and 2.4%6.8% for the three months ended SeptemberJune 30, 20212022 and 2020,2021, respectively. Changes in foreign currency translation rates decreased our revenue by 5.8% and increased our revenue by 4.5% and 0.1%6.5% for the ninesix months ended SeptemberJune 30, 2022 and 2021, and 2020, respectively.
Assets and liabilities of our foreign subsidiaries, where the functional currency is the local currency, are translated into U.S. dollars usingSeptemberJune 30, 20212022 and 2020,2021, we recorded net gains (losses) from currency translation adjustments of $(26.6)$(76.9) million and $8.6$14.3 million, respectively. For the ninesix months ended SeptemberJune 30, 20212022 and 2020,2021, we recorded net gains (losses)losses from foreign currency translation of $(80.2)$(107.4) million and $5.1$(53.6) million, respectively. Gains and losses resulting from foreign currency transactions are reported in interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income.
We periodically enter into forward currency contracts in order to minimize the volatility that fluctuations in currency translation have on our monetary transactions. Under these arrangements, we typically agree to purchase a fixed amount of a foreign currency in exchange for a fixed amount of U.S. dollars or other currencies on specified dates with maturities of less than twelve months, with some agreements extending to longer periods. These transactions do not qualify for hedge accounting and, accordingly, the instrument is recorded at fair value with the corresponding gains and losses recorded in the unaudited condensed consolidated statements of income and comprehensive income.
As of SeptemberJune 30, 2021,2022, we have several cross-currency and interest rate swap agreements with a notional value of $150.0$148.9 million of U.S. dollar to Swiss Franc and a notional value of $355.0$248.9 million of U.S. dollar to Euro to hedge the variability in the movement of foreign currency exchange rates on portions of our Euro and Swiss Franc denominated net asset investments. Under the GAAP hedge accounting guidance, changes in fair value of the derivative that relates to changes in the foreign currency spot rate are recorded in the currency translation adjustment in comprehensive income (loss) and remain in accumulated comprehensive income (loss) in shareholders’ equity until the sale or substantial liquidation of the foreign operation. For the three months ended SeptemberJune 30, 20212022 and 2020,2021, we recorded net gains from the changes in fair value of the derivatives of $8.4$18.0 million and net lossesgains of $22.1$1.1 million, respectively. For the ninesix months ended SeptemberJune 30, 20212022 and 2020,2021, we recorded net gains from the changes in fair value of the derivatives of $37.2$30.1 million and net losses of $22.4$28.8 million, respectively.
On December 7, 2021, we entered into a note purchase agreement, referred to as the 2021 Note Purchase Agreement, with a group of institutional accredited investors. Pursuant to the 2021 Note Purchase Agreement, we issued and sold CHF 300 million aggregate principal amount of 0.88% series A senior notes and EUR 150 million aggregate principal amount of 1.03% series B senior notes due December 8, 2031. We designated our CHF 300 million series A senior notes as a hedge in our net investment in our Swiss Franc denominated net assets. We designated our EUR 150 million series B senior notes as a hedge in our net investment in our Euro
40
denominated net assets. Accordingly, the change in fair value of the 2021 Note Purchase Agreement is recorded in other comprehensive income within derivatives designated as hedging instruments, net of tax.
On December 11, 2019, we entered into a note purchase agreement, referred to as the 2019 Note Purchase Agreement, with a group of institutional accredited investors. Pursuant to the 2019 Note Purchase Agreement, we issued and sold CHF 297 million aggregate principal amount of 1.01% senior notes due December 11, 2029. We designated our CHF 297 million senior notes as a hedge in our net investment in our Swiss Franc denominated net assets. Accordingly, the change in fair value of the 2019 Note Purchase Agreement is recorded in other comprehensive income within derivatives designated as hedging instruments, net of tax.
For the three months ended SeptemberJune 30, 20212022 and 2020,2021, we recorded net gains (losses) from the changes in fair value, net of tax, of the 2021 Note Purchase Agreement and the 2019 Note Purchase Agreement of $2.2$23.5 million and $(8.2)$(0.7) million, respectively. For the ninesix months ended SeptemberJune 30, 20212022 and 2020,2021, we recorded net gains (losses) from the changeschange in fair value, net of tax, of the 2021 Note Purchase Agreement and the 2019 Note Purchase Agreement of $22.2$32.5 million and $(15.3)$20.0 million, respectively.
From time to time, we have entered into forward exchange contracts designed to minimize the volatility that fluctuations in foreign currency have on our cash flows related to purchases and sales denominated in foreign currencies. Under these arrangements, we agree to purchase a fixed amount of a foreign currency in exchange for a fixed amount of U.S. dollars or other currencies on specified dates typically with maturities of less than twelve months with some agreements extending to longer periods. These transactions are recorded at fair value with the corresponding gains and losses recorded in interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income. At SeptemberJune 30, 20212022 and December 31, 2020,2021, we had foreign exchange contracts with notional amounts aggregating $124.5$130.3 million and $278.3$180.7 million, respectively. We will continue to evaluate our currency risks and in the future may utilize foreign currency contracts more frequently.
Interest Rate Risk
We regularly invest excess cash in short-term investments that are subject to changes in interest rates. We believe that the market risk arising from holding these financial instruments is minimal because of our policy of investing in short-term financial instruments issued by highly rated financial institutions.
Our exposure related to adverse movements in interest rates is derived primarily from outstanding floating rate debt instruments that are indexed to short-term market rates. We currently have a higher level of fixed rate debt than variable rate debt, which limits the exposure to adverse movements in interest rates.
Commodity Price Risk
We are exposed to certain commodity risks associated with prices for various raw materials. The prices of copper and certain other raw materials, particularlySeptemberJune 30, 20212022 and December 31, 2020,2021, we had fixed price commodity contracts with notional amounts aggregating $4.5$9.0 million and $8.8$5.5 million, respectively. The fair value of the fixed price commodity contracts at SeptemberJune 30, 20212022 and December 31, 20202021 was $0.8$(1.0) million and $3.1$0.4 million, respectively. As commodity contracts settle, gains (losses) as a result of changes in fair values are adjusted to the contracts with the customers through revenues. We will continue to evaluate our commodity risks and may utilize commodity forward purchase contracts more frequently in the future.
Inflation Risk
We do not believeare subject to inflationary cost pressures across global supply chain networks. Certain components, parts, or materials are experiencing significant cost pressures that have impacted or may impact our cost of operations in future periods. Further, inflation hadhas increased our general and administrative expenses and may vary between countries in which we operate. We continue to evaluate these cost increases in relation to our new orders and may continue to see a materialnegative impact on our business or operatingfinancial results during anyfor a period of the periods presented.
41
ITEM 4. CONTROLS AND PROCEDURES
We have established disclosure controls and procedures (as defined in RulesSeptemberJune 30, 2021.2022. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of SeptemberJune 30, 2021.
Management concluded that the unaudited condensed consolidated financial statements contained in this Quarterly Report on Form
Changes in Internal Controls over Financial Reporting
There have been no changes in our internal control over financial reporting during the three months ended SeptemberJune 30, 20212022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
42
PART II OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We are involved in lawsuits, claims, and proceedings, including, but not limited to, patent and commercial matters, which arise in the ordinary course of business. There are no such matters pending that we currently believe are reasonably likely to have a material impact on our business or to our condensed consolidated financial statements.
On September 25, 2019, in a complaint filed in the District Court of Düsseldorf, Germany, District Court, Carl Zeiss Microscopy GmbH, a subsidiary of Carl Zeiss AG (Zeiss), sued Luxendo GmbH (Luxendo), a subsidiary of Bruker Corporation, for infringement of a recently registered German utility model patent licensed to Zeiss pertaining to one specific Luxendo product category. Zeiss is seeking injunctive relief, an accounting indemnification for damages resulting from infringement, and other, related remedies. We are vigorously defending against this claim.
In addition, we are subject to regulation by national, state and local government agencies in the United States and other countries in which we operate. From time to time, we are the subject of governmental investigations often involving regulatory, marketing and other business practices. These governmental investigations may result in the commencement of civil and criminal proceedings, fines, penalties and administrative remedies which could have a material adverse effect on our financial position, results of operations and/or liquidity.
ITEM IA. RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form2020,2021, which could materially affect our business, financial condition or future results. The risks described in this report and in our Annual Report on Form
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The following table provides information about purchases made by theCOVID-19pandemic.
Period |
| Total Number of Shares Purchased (1) |
|
| Average Price Paid per Share |
|
| Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |
|
| Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Program (2) |
| ||||
April 1 - April 30, 2022 |
|
| — |
|
| $ | — |
|
|
| — |
|
| $ | 275,538,707 |
|
May 1 - May 31, 2022 |
|
| 459,791 |
|
| $ | 60.00 |
|
|
| 458,081 |
|
| $ | 248,049,102 |
|
June 1 - June 30, 2022 |
|
| 525,660 |
|
| $ | 62.36 |
|
|
| 525,660 |
|
| $ | 215,270,146 |
|
|
|
| 985,451 |
|
| $ | 61.26 |
|
|
| 983,741 |
|
| $ | 215,270,146 |
|
43
ITEM 6. EXHIBITS
Exhibit No. | Description | |
10.1* | ||
31.1* | Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
31.2* | Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
32.1* | ||
101.INS* | Inline XBRL Instance Document | |
101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
104* | The cover page from the Company’s Quarterly Report on Form |
* Filed or furnished herewith.
44
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: August 5, 2022 | BRUKER CORPORATION | |||||
By: | /s/ FRANK H. LAUKIEN, PH.D. | |||||
Frank H. Laukien, Ph.D. | ||||||
President, Chief Executive Officer and Chairman | ||||||
(Principal Executive Officer) | ||||||
Date: | By: | /s/ GERALD N. HERMAN | ||||
Gerald N. Herman | ||||||
Executive Vice President and Chief Financial Officer | ||||||
(Principal Financial Officer and Principal Accounting Officer) | ||||||
45